Protected when completed

Date Submitted: 2025-01-31 02:20:02
Confirmation Number: 1903762
Template: CIHR Biosketch

Dr. FEI GENG

Correspondence language: English
Sex: Male
Date of Birth: 10/27
Canadian Residency Status: Canadian Citizen
Country of Citizenship: Canada

Contact Information

The primary information is denoted by (*)

Address

Primary Affiliation (*)

W Booth School of Engineering Practice
ETB-203
McMaster University
1200 Main Street West
CANADA (L8N 3Z5)
Hamilton Ontario L8N 3Z5
Canada

Telephone

Mobile (*)	001-905-9029163
Work	001-905-5259140 extension: 20285

Email

Work (*)	gengf@mcmaster.ca

Website

Personal	https://www.eng.mcmaster.ca/people/faculty/fei-geng

CIHR IRSC
Canadian Institutes of Health Research | Instituts de recherche en santé du Canada

Canadian Common CV commun canadien

Protected when completed

Dr. FEI GENG

Degrees

2004/9 - 2011/12	Doctorate, Doctor of Philosophy, McMaster University Degree Status: Completed
2001/9 - 2004/8	Master's Thesis, Master of Science, Fudan University Degree Status: Completed
1996/9 - 2001/7	Bachelor's Honours, Bachelor of Medicine, Jining Medical College Degree Status: Completed

Credentials

2016/2	P.Eng., Professional Engineers Ontario

Recognitions

2021/8	Michael G. DeGroote Institute Research Award McMaster University
2018/9 - 2019/4	Dean's Honor Roll McMaster University

Employment

2022/3	Associate Professor W Booth School of Engineering Practice and Technology, Engineeering, McMaster University
2020/7	Program Chair in Biotechnology W Booth School of Engineering Practice and Technology, Engineeering, McMaster University
2019/4	Assistant Professor W Booth School of Engineering Practice and Technology, Engineeering, McMaster University

Affiliations

The primary affiliation is denoted by (*)

(*) 2013/5	Associate Professor, McMaster University

Research Funding History

Awarded [n=6]

2024/7 - 2025/7
Principal Investigator

Advancing Early Detection of Lung Cancer through Multiplex Lateral Flow-Based Liquid Biopsy: A Blood Based Pre-Screening Approach

Funding Sources:
AstraZeneca Canada Inc.
Lung Ambition Award
Total Funding - 50,000
Funding Competitive?: Yes

2022/9 - 2024/8
Principal Investigator

YAP mechanotransduction in autophagy and tumor metastasis

Funding Sources:
Mathematics of Information Technology and Complex Systems (MITACS)
Accelerate
Total Funding - 60,000
Funding Competitive?: Yes

2019/10 - 2022/12
Principal Applicant

Targeting platelet-neutrophil axis: a novel therapeutic approach for Scleroderma

Funding Sources:
Mathematics of Information Technology and Complex Systems (MITACS)
Accelerate
Total Funding - 60,000
Funding Competitive?: Yes

2021/8 - 2022/7
Principal Applicant

The proteomic profiling of pain signatures for post-surgical patients

Funding Sources:
Michael G. DeGroote Institute for Pain Research and Care
IPRC Catalyst Grant
Total Funding - 60,000
Funding Competitive?: Yes

2018/2 - 2022/2
Co-applicant

Development of cost-effective label-free protein biosensors using magnetic bio-inks

Funding Sources:
Natural Sciences and Engineering Research Council of Canada (NSERC)
Collaborative Research and Development (CRD) Grant
Total Funding - 565,000
Funding Competitive?: Yes

Principal Applicant : Ishwar Puri

2018/11 - 2020/11
Principal Applicant

The molecular mechanism of autophagy in systemic sclerosis and its clinical implication

Funding Sources:
Scleroderma Society of Ontario
Scleroderma Research Grant
Total Funding - 25,000
Funding Competitive?: Yes

Publications

Journal Articles

1. Su Z, Wu Y, Ge C, Barooj S, Hirota JA, Geng F. (2024). Deciphering the Mechanotransduction Symphony: Stiffness-Dependent Interplay of YAP and β-Catenin in Breast Cancer Metastasis. iScience. N/A: N/A.
In Press
Refereed?: Yes

2. Grewal, R*; Ortega, GA; Geng, F; Srinivasan, S; Rajabzadeh, AR. (2024). Label-free electrochemical detection of glycated hemoglobin (HbA1c) and C-reactive protein (CRP) to predict the maturation of coronary heart disease due to diabetes. Bioelectrochemistry. 159: 108743.
Published
Refereed?: Yes, Open Access?: Yes

3. Lin C.Y., Sassi A., Wu Y., Seaman K., Tang W., Song X., Bienenstock R., Yokota H., Sun Y., Geng F., Wang L., You L. (2024). Mechanotransduction pathways regulating YAP nuclear translocation under Yoda1 and vibration in osteocytes. Bone. 190: 117283.
Published
Refereed?: Yes, Open Access?: Yes

4. Ge, C*; Selvaganapathy, PR; Geng, F. (2023). Advancing our understanding of bioreactors for industrial-sized cell culture: health care and cellular agriculture implications. American Journal of Physiology-Cell Physiology. 20230724: 20230724.
Published
Refereed?: Yes

5. Raha, A; Wu, Y; Zhong, L; Raveenthiran, J; Hong, M; Taiyab, A; Wang, L; Wang, B; Geng F. (2023). Exploring Piezo1, Piezo2, and TMEM150C in Human Brain Tissues and Their Correlation with Brain Biomechanical Characteristics. Molecular Brain. 16: 83.
Published
Refereed?: Yes, Open Access?: Yes

6. Tsai, Y; Nanthakumar, V; Mohammadi, S; Baldwin, SA; Gopaluni, B; Geng F. (2023). Targeted Deep Learning Classification and Feature Extraction for Clinical Diagnosis. iScience. 26(11): 108006.
Published
Refereed?: Yes, Open Access?: Yes

7. Song, X; Lin, CY; Raha, A, Ke, Y, Wang, L, Geng, F; You, L. (2022). Vibration in Preventing Breast Cancer Bone Metastasis. Journal of bone and mineral research. 37: 202.
Published
Refereed?: Yes

8. Wang, Y; et al. (2022). The CaT stretcher: An open-source system for delivering uniaxial strain to cells and tissues (CaT). Frontiers in Bioengineering and Biotechnology. 10: 959335.
Published
Refereed?: Yes

9. Wasi, M; Wang, S; Xiong, J; Geng, F; You, L; Wang, L. (2022). Longitudinal Monitoring of Breast Cancer-Induced Osteolysis in Aged Female Mice. Journal of bone and mineral research. 37: 202-203.
Published
Refereed?: Yes

10. *Yu, W; *Bai, Y; *Raha, A, *Su, Z; Geng, F. (2022). Integrative In Silico Investigation Reveals the Host-Virus Interactions in Repurposed Drugs Against SARS-CoV-2. Front. Bioinform.11 January 2022: 11 January 2022.
Published
Refereed?: Yes

11. Lin, CY; Song, X; Ke, Y; Raha, A; Wu, Y; Wasi, M; Wang, L; Geng, F; You, L. (2022). Yoda1 Enhanced Low-Magnitude High-Frequency Vibration on Osteocytes in Regulation of MDA-MB-231 Breast Cancer Cell Migration. Cancers. 14(14): 3395.
Published
Refereed?: Yes

12. Chen, W*; Park, S*; Patel, C*; Bai, Y*; Henary, K*; Raha, A*; Mohammadi, S; You, L; Geng, F. (2021). The migration of metastatic breast cancer cells is regulated by matrix stiffness via YAP signalling. Heliyon. 7(2): e06252.
Published
Refereed?: Yes, Open Access?: Yes

13. Gupta, T*; Aithal, S; Mishriki, S*; Sahu, RP; Geng, F; Puri IK. (2020). Label-Free Magnetic-Field-Assisted Assembly of Layer-on-Layer Cellular Structures. ACS Biomaterials Science & Engineering. 6(7): 4294-4303.
Published
Refereed?: Yes, Open Access?: No

14. Mishriki, S; Aithal, S; Gupta, T; Sahu, RP; Geng, F; Puri IK. (2020). Fibroblasts Accelerate Formation and Improve Reproducibility of 3D Cellular Structures Printed with Magnetic Assistance. Research. 2020: 3970530.
Published
Refereed?: Yes, Open Access?: Yes

15. Kong,Q; Xiang,Z; Wu,Y; Gu,Y; Guo,J; Geng,F. (2020). Analysis of the susceptibility of lung cancer patients to SARS-CoV-2 infection.Mol Cancer. 19(1): 80.
Published
Refereed?: Yes, Open Access?: Yes

16. Chen,W*; Bai,Y*; Patel,C*; Geng,F. (2019). Autophagy promotes triple negative breast cancer metastasis via YAP nuclear localization. Biochem Biophys Res Commun.520(2): 263-268.
Published
Refereed?: Yes

17. Abdel Fattah,A*; Mishriki,S*; Kammann,T; Sahu,R*; Geng,F; Puri,I. (2018). Gadopentatic acidaffects in vitro proliferation and doxorubicin response in human breastadenocarcinoma cells. Biometals. 31(4): 605-616.
Published
Refereed?: Yes, Open Access?: No

18. Abdel Fattah,A*; Mishriki,S*; Kammann,T; Sahu,R*; Geng,F; Puri,I. (2018). 3D cellularstructures and co-cultures formed through the contactless magnetic manipulationof cells on adherent surfaces. Biomaterials Science. 6(3): 683-694.
Published
Refereed?: Yes, Open Access?: No

19. Mishriki,S*; Abdel Fattah,A*; Kammann,T; Sahu,R*; Geng,F; Puri,I. (2018). Rapid magnetic 3D printing of cellular structures with MCF-7 cell inks. Research. 2019: 9854593.
Published
Refereed?: Yes, Open Access?: No

Conference Publications

1. Abdel Fattah AR*, Abdalla AM, Mishriki S*, Meleca E*, Ghosh S*, Geng F, Puri IK. Magnetic printing of a biosensor: inexpensive rapid sensing to detect picomolar amounts of antigen with antibody-functionalized carbon nanotubes. 28th Anniversary World Congress on Biosensors, Miami, United States of America Abstract
Refereed?: Yes, Invited?: Yes

2. Chen, W*; Raha, A*; Geng, F. The regulation of breast cancer metastasis by YAP mechanotransduction. 64th Annual Conference of the Canadian Society of Molecular Biosciences (CSMB), Montréal, Canada
Conference Date: 2021/6
Abstract
Refereed?: Yes, Invited?: No

3. Chen W*, Patel C*, Bai Y*, Geng F. The regulation of autophagy via YAP signaling in systemic sclerosis. The 25th Canadian Connective Tissue Conference, Montreal, Canada
Conference Date: 2019/5
Abstract
Refereed?: Yes, Invited?: Yes

4. Mishriki S*, Geng F. In situ contactless 3D printing of cellular structures. International Mechanical Engineering Congress & Exposition (IMECE) 2018, Pittsburgh, PA, United States of America
Conference Date: 2018/11
Abstract
Refereed?: Yes, Invited?: Yes

5. Mishriki S*, Geng F. Magnetic antibody functionalized carbon nanotube ink for rapid printing of biosensors. International Mechanical Engineering Congress & Exposition (IMECE) 2018, Pittsburgh, PA, United States of America
Conference Date: 2018/11
Abstract
Refereed?: Yes, Invited?: Yes

Intellectual Property

Licenses

1. P.Eng.
Granted
Date Issued: 2016/2
Filing Date: 2023/03/16

Presentations

1. Fei Geng. (2021). The regulation of breast cancer metastasis by YAP mechanotransduction. 64th Annual Conference of the Canadian Society of Molecular Biosciences (CSMB), Canada
Main Audience: Researcher
Invited?: No, Keynote?: No

2. Fei Geng. (2019). The regulation of autophagy via YAP signaling in systemic sclerosis. The 25th Canadian Connective Tissue Conference, Canada
Main Audience: Researcher
Invited?: Yes, Keynote?: No

3. Sarah Mishriki, Fei Geng. (2018). Magnetic Printing of a Biosensor: Inexpensive Rapid Sensing To Detect Picomolar Amounts of Antigen with Antibody- Functionalized Carbon Nanotubes. 28th Anniversary World Congress on Biosensors, United States of America
Main Audience: Researcher
Invited?: Yes, Keynote?: No

4. Sarah Mishriki, Fei Geng. (2018). Magnetic Antibody Functionalized Carbon Nanotube Ink for Rapid Printing of Biosensors. International Mechanical Engineering Congress & Exposition (IMECE), United States of America
   Main Audience: Researcher
   Invited?: Yes, Keynote?: No
5. Sarah Mishriki, Fei Geng. (2018). In Situ Contactless 3D Printing of Cellular Structures. International Mechanical Engineering Congress & Exposition, United States of America
   Main Audience: Researcher
   Invited?: Yes, Keynote?: No

Student/Postdoctoral Supervision

Master's Thesis [n=3]

2022/1 - 2024/1 Principal Supervisor	Zhi Su, McMaster University Thesis/Project Title: YAP regulation in the mechanotransduction of breast cancer metastasis Present Position: Master's student
2022/1 - 2023/12 Principal Supervisor	Yuning Wu, McMaster University Thesis/Project Title: Beta-catenin regulation in the mechanotransduction of breast cancer metastasis Present Position: Master's student
2019/9 - 2022/8 Principal Supervisor	Wei Chen, McMaster University Thesis/Project Title: The regulation of YAP signaling network in cellular mechanotransduction Present Position: Scientist

Doctorate [n=3]

2020/9 - 2025/8 Principal Supervisor	Arjun Raha, McMaster University Thesis/Project Title: The significance of O-GlcNAcylation in YAP mediated mechanotransduction Present Position: Ph.D. student
2018/11 - 2022/8 Co-Supervisor	Tamaghna Gupta, McMaster University Thesis/Project Title: The development of 3D cell culture system for cellular mechanotransduction studies Present Position: Ph.D. student
2018/1 - 2021/1 Co-Supervisor	Sarah Mishriki, McMaster University Thesis/Project Title: In situ 3D cell assemblies through a contactless method-diamagnetophoresis Present Position: Ph.D. candidate

Post-doctorate [n=2]

2022/7 - 2024/7 Principal Supervisor	Yiting Tsai, McMaster University Thesis/Project Title: Biomarker discovery and proteomic profiling via machine learning Present Position: Postdoc Fellow

2020/5 - 2022/5	Saeed Mohammadi, McMaster University
Principal Supervisor	Thesis/Project Title: The development of extracellular matrix with tunable stiffness for the mechanotransduction study Present Position: Postdoctoral researcher

Protected when completed

Date Submitted: 2024-02-27 15:55:59
Confirmation Number: 1750479
Template: Full CV

Dr. Rosalyn Juergens

Correspondence language: English
Sex: Female
Date of Birth: 8/23
Canadian Residency Status: Permanent Resident
Permanent Residency Start Date: 2010/12/20
Country of Citizenship: United States of America

Contact Information

The primary information is denoted by (*)

Address

Primary Affiliation (*)

699 Concession Street
Juravinski Cancer Centre
Fourth Floor - Room 228
Hamilton Ontario L8V 5C2
Canada

Telephone

Work (*)	1-905-3879495 extension: 63123

Email

Work (*)	juergensr@hhsc.ca

Website

Corporate	https://experts.mcmaster.ca/display/juergen
Corporate	http://www.everypatientmatters.ca/researchers/9

Protected when completed

Dr. Rosalyn Juergens

Language Skills

Language	Read	Write	Speak	Understand	Peer Review
English	Yes	Yes	Yes	Yes	
French	No	No	No	No	

Degrees

2004/8 - 2012/5

Doctorate, PhD, Clinical Investigation, Johns Hopkins University
Degree Status: Completed
Thesis Title: Targeting Epigenetic Changes in Lung Cancer

Supervisors: Charles Rudin, MD PhD

Research Disciplines: Oncology

Areas of Research: Lung Cancer

Fields of Application: Pathogenesis and Treatment of Diseases

2003/7 - 2006/6

Doctorate, Medical Oncology Fellowship - Fellow, Medical Oncology, Johns Hopkins University
Degree Status: Completed

Supervisors: Ross Donehower, MD

2000/7 - 2003/6

Doctorate, Internal Medicine Internship and Residency, Internal Medicine, Johns Hopkins University
Degree Status: Completed

Supervisors: Charles Weiner, MD

1996/8 - 2000/5

Doctorate, M.D., Medicine, Georgetown University
Degree Status: Completed

Supervisors: Mitchell, Stephen

1992/8 - 1996/5

Bachelor's, Bachelor of Science, Biological Research, Loras College
Degree Status: Completed
Thesis Title: Identification of Proteins Binding to the Brachial Regulatory Element of the Brachial Spinal Chord Enhancer of Murine Homeobox Gene A5

Supervisors: Eagleson, Gerald

Research Disciplines: Molecular Biology

Areas of Research: Biological and Biochemical Mechanisms

Credentials

2011/1	License to practice medical oncology, College of Physicians and Surgeons of Ontario Medical Oncology
2006/1	Board Certification in Medical Oncology, American Board of Internal Medicine Medical Oncology
2003/1 - 2023/5	License to practice medicine, Maryland Board of Physicians Internal Medicine and Medical Oncology
2003/1 - 2013/12	Board Certification in Internal Medicine, American Board of Internal Medicine Internal Medicine

Recognitions

	Teacher of the Year - Medical Oncology (Canadian dollar) McMaster University Distinction
2021/6	American Society of Clinical Oncology - Women Who Conquer Cancer Award Finalist (Canadian dollar) Distinction
2018/6	Teacher of the Year - Medical Oncology McMaster University Distinction
2018/4	Phase III Program Team Award Canadian Cancer Trials Group Prize / Award
2016/4	Investigational New Drug Program Team Award Canadian Cancer Trials Group Prize / Award
2012/5	Membership in Delta Omega Johns Hopkins University Distinction Membership in public health honor society
2012/5	Membership in Phi Beta Kappa Johns Hopkins University Distinction Membership in academic honor society
2005/5	Clinical Researcher Annual International Award Johns Hopkins Bloomberg School of Public Health Distinction Clinical Research
1999/5	Alpha Omega Alpha Georgetown University Distinction

User Profile

Researcher Status: Researcher
Research Career Start Date: 2007/07/01
Engaged in Clinical Research?: Yes

Research Interests: I have interests in multiple areas of clinical and translational research. I have focused mainly on lung and esophageal cancers. My key interests include epigenetics, immune-based therapies, genetically and epigenetically directed therapy, biomarkers in cancer, and functional imaging using PET.

Research Experience Summary: I have been involved as a principal investigator in numerous clinical trials. I have clinical research experience with several immune based therapies (such a PD-1 inhibitors and tumour directed viruses) as well as epigenetic directed therapy (demethylating agents and histone deacetylase inhibitors). In addition to my clinical research work I have contributed to at least weekly meetings with my basic science collaborators in epigenetics helping to guide pre-clinical experiments and taking laboratory experiment data back to inform our clinical trial development.

Research Specialization Keywords: clinical research, developmental therapeutics, epigenetics, esophageal cancer, Immunotherapy, lung cancer, molecular imaging, translational research

Disciplines Trained In: Epidemiology and Biostatistics, Molecular Biology, Oncology

Research Disciplines: Molecular Biology, Nuclear Medicine, Oncology

Areas of Research: Cancer Diagnosis and Detection, Cancer Genetics, Cancer of the Digestive System, Chemotherapy, Lung Cancer

Fields of Application: Pathogenesis and Treatment of Diseases

Employment

2023/4	Early Trials Advisory Group Member - Canadian Cancer Trials Group
2016/9	Chair, Clinical Trials, Juravinski Cancer Centre Oncology, McMaster University, Juravinski Cancer Centre Full-time, Term, Associate Professor
2016/7	Associate Professor Oncology, McMaster University, McMaster University Full-time, Associate Professor
2015/7	Chair, Medical Advisory Committee Lung Cancer Canada
2011/1	Assistant Professor Department of Oncology, McMaster University, McMaster University Full-time, Assistant Professor
2011/1	Adjunct Assistant Professor Department of Oncology, The Johns Hopkins University, Johns Hopkins University Part-time, Assistant Professor
2017/5 - 2024/4	Investigational New Drug Committee - Executive member Canadian Cancer Trials Group
2013/3 - 2023/7	Chair, Lung Disease Site Team Juravinski Cancer Centre
2019/5 - 2021/11	Chair, Investigational New Drug Committee Canadian Cancer Trials Group
2009/7 - 2010/12	Assistant Professor Medicine, The Johns Hopkins University, Johns Hopkins University Full-time, Assistant Professor
2007/7 - 2010/12	Assistant Professor Department of Oncology, The Johns Hopkins University, Johns Hopkins University Full-time, Assistant Professor

2006/7 - 2007/6 Chief Fellow - Medical Oncology
Department of Oncology, The Johns Hopkins University, Johns Hopkins University
Full-time

Affiliations

The primary affiliation is denoted by (*)

(*) 2016/7 Associate Professor, McMaster University

2011/1 Assistant Professor, McMaster University

Leaves of Absence and Impact on Research

2012/11 - 2013/6 Parental, McMaster University
I was on pregnancy / parental leave from late November 2012 through the end of May 2013. During this period I had reduced activity in my translational research endeavours.

2011/4 - 2011/9 Parental, McMaster University
Maternity leave

Research Funding History

Awarded [n=24]

2022/4 - 2027/3
Principal Applicant
Canadian Cancer Clinical Trials Network Cancer Centre Grant, Grant, Operating

2024/4 - 2026/3
Principal Investigator
GUT-INSTINCTS- Understanding the effect of the microbiome on response to neoadjuvant treatment with chemotherapy + immunotherapy in patients with resectable non-small cell lung cancer (NSCLC)., Grant, Operating
Clinical Research Project?: Yes

Funding Sources:

Hamilton Academic Health Sciences Organization
Total Funding - 177,294 (Canadian dollar) (Canadian dollar)

2024/1 - 2025/6
Co-investigator
MATCH 3.0: Liquid vs solid tissue biopsy for mutation and translocation detection in non-squamous non-small cell lung cancer., Grant, Operating
Clinical Research Project?: Yes

Funding Sources:

Hamilton Health Sciences Foundation
Total Funding - 100,000 (Canadian dollar) (Canadian dollar)

2024/1 - 2025/1
Principal Applicant
Liquid vs solid tissue biopsy for mutation and translocation detection in non-squamous non-small cell lung cancer: Improving equity in cancer care delivery across Central-West Ontario., Grant, Operating
Clinical Research Project?: Yes

Funding Sources:

Pfizer Canada, Lung Health Foundation; Lung Cancer Canada; Quebec Lung Association
Total Funding - 100,000 (Canadian dollar) (Canadian dollar)

2024/1 - 2024/1
Co-investigator
MATCH 2.0: Liquid vs solid tissue biopsy for mutation and translocation detection in non-squamous non-small cell lung cancer: Improving equity in cancer care delivery across Central-West Ontario., Grant

Clinical Research Project?: Yes

Funding Sources:

AstraZeneca Canada Inc.
Total Funding - 150,000 (Canadian dollar) (Canadian dollar)

2018/4 - 2022/3
Principal Applicant

Canadian Cancer Clinical Trials Network Cancer Centre Grant, Grant, Grant, Operating

2017/9 - 2021/8
Principal Investigator

Drug Resistance in Bodily Fluids Evaluation (DRIBLE)

Funding Sources:

2017/9 - 2019/8 AstraZeneca Canada Inc.
-
Total Funding - 100,000 (Canadian dollar)
Funding Competitive?: Yes

2017/6 - 2021/1
Principal Investigator

Optimization of PD-L1 Testing in Hamilton

Funding Sources:

2017/6 - 2019/1 Merck Sharp & Dohme - Canada
IIT
Total Funding - 40,000 (Canadian dollar)
Funding Competitive?: No

2017/9 - 2019/8
Principal Investigator

Utility of PD-L1 Testing in 2nd line NSCLC - Substudy of CA209-169

Funding Sources:

2017/2 - 2018/8 Bristol-Myers Squibb Canada Inc.
-
Total Funding - 33,000 (Canadian dollar)
Funding Competitive?: Yes

2014/4 - 2019/3
Principal Applicant

Pilot of platform molecular testing in lung cancer

Funding Sources:

2014/5 - 2016/4 Juravinski Cancer Centre Foundation
Annual Gala Competition
Total Funding - 75,000 (Canadian dollar)
Funding Competitive?: Yes

Co-investigator : Elizabeth McCready; JC Cutz; Peter Ellis

2017/9 - 2018/8
Co-knowledge User

Developing a Tool to Support Earlier Palliative Care

Funding Sources:

2017/9 - 2018/8 Canadian Institutes of Health Research (CIHR)
-
Total Funding - 100,000 (Canadian dollar)
Funding Competitive?: Yes

Principal Investigator : Hsien Seow

2015/8 - 2017/7
Principal Applicant

A phase IB study of durvalumab (MEDI4736) with or without tremelimumab in patients with advanced incurable solid malignancies receiving standard chemotherapy regimens, Contract
Clinical Research Project?: Yes

Funding Sources:

2015/8 - 2017/7 National Cancer Institute of Canada (NCIC)
Total Funding - 125,000 (Canadian dollar)
Funding Competitive?: No

2015/7 - 2017/6
Principal Applicant

A randomized phase II trial of maintenance therapy with talazoparib or placebo in patients with extensive disease small cell lung cancer, Contract
Clinical Research Project?: Yes

Funding Sources:

2015/7 - 2017/6 National Cancer Institute of Canada (NCIC)
Total Funding - 69,000 (Canadian dollar)
Funding Competitive?: No

2011/1 - 2017/6
Principal Investigator

Imaging scientist award for development of translational research coordinating medical oncology therapeutics and investigational imaging technologies.

Funding Sources:

2011/1 - 2016/12 Ontario Institute for Cancer Research (OICR)
Investigator Awards Program
Total Funding - 1,450,000 (Canadian dollar)
Funding Competitive?: Yes

Principal Investigator : Rosalyn Juergens

2014/12 - 2016/11
Principal Investigator

Leveraging Research Discoveries in Hamilton: A Collaborative Clinical Study on Targeted Alpha Radionuclide Therapy for Treatment Resistant Cancers

Funding Sources:

2014/11 - 2016/10 Boris Family Award
Boris Scholars Award
Total Funding - 294,500 (Canadian dollar)
Funding Competitive?: Yes

Co-investigator : John Valliant; Karen Gulenchyn; Mark Levine

2009/12 - 2016/11
Co-investigator

Bringing epigenetic therapy to the forefront of cancer management

Funding Sources:

2009/12 - 2012/11 American Association of Cancer Research (AACR)
Stand up to Cancer Dream Team - SU2C-AACR-CT0109
Total Funding - 2,337,852 (United States dollar)
Funding Competitive?: Yes

Principal Investigator : Baylin, Stephen

2014/5 - 2015/4
Principal Investigator

Phase Ia, multi-centre, open-label, non-randomized study to assess the safety, biodistribution and tumour uptake of [I-124]-CPD-1028 Injection

Funding Sources:

2014/5 - 2015/4 Centre for Probe Development and Commercialization
Phase I development program in novel imaging probes
Total Funding - 150,000 (Canadian dollar)
Funding Competitive?: No

Co-investigator : Bane, Anita; Gulenchyn, Karen; Hotte, Sebastien; McWhirter, Elaine; Mukherjee, Som; Singnurkar, Amit

2013/4 - 2015/3
Co-applicant

Evaluation of a patient-focused, nurse navigated esophageal cancer disease management pathway program

Funding Sources:

2013/4 - 2015/3 Hamilton Academic Health Sciences Organization (HAHSO)
Innovation Grant Program
Total Funding - 177,260 (Canadian dollar)
Funding Competitive?: Yes

Co-applicant : Boylan, Colm; Dhesy-Thind, Sukhbinder; Farrokhyar, Forough; Shargall, Yaron; Sur, Ranjan; Woods, Anne;

Principal Applicant : Finley, Christian

2013/1 - 2014/12
Principal Investigator

Trial of two combinations of radiation and chemotherapy in resectable cancer of the esophagus and stomach, Grant, Operating
Clinical Research Project?: Yes
Project Description: The objective of this study is to examine 2 treatment options. One group of patients will receive brachytherapy followed by chemotherapy before surgery while the other group will receive the same chemotherapy and the usual type of external radiation followed by surgery. After surgery the pathologist will determine the number of patients who have no cancer left ('complete pathologic response'). Secondary objectives will determine the time it takes for the tumor to come back, the location within the body where the cancer comes back, and differences in swallowing scores. Eligible patients will have esophageal cancer and be a candidate for curative surgery. Patients must be fit enough to tolerate the treatment and not have any other major medical problems. Patients with other types of cancers will be excluded. A total of 60 patients will be included and randomly assigned to a treatment option as explained above.

Funding Sources:

2013/1 - 2014/12 Juravinski Cancer Centre Foundation
Fall Grants Competition
Total Funding - 100,000 (Canadian dollar)
Funding Competitive?: Yes

2011/11 - 2014/10
Co-applicant

18F-Sodium Fluoride PET imaging as a replacement for bone scintigraphy

Funding Sources:

2011/11 - 2014/10 Medical Imaging Trial NEtwork of Canada
Theme 1: Oncology Imaging
Total Funding - 697,655 (Canadian dollar)
Funding Competitive?: Yes

Co-applicant : Goodbody, Anne; Pond, Greg; Valliant, John; Wong-Pack, William;

Principal Applicant : Gulenchyn, Karen

2012/3 - 2014/2
Principal Investigator

A Single Arm, Phase 2 Study of Ganetespib in Subjects with Advanced Non-Small-Cell Lung Cancer with Anaplastic Lymphoma Kinase Gene Rearrangement (ALK-Positive NSCLC)., Contract
Clinical Research Project?: Yes
Project Description: A Single Arm, Phase 2 Study of Ganetespib in Subjects with Advanced Non-Small-Cell Lung Cancer with Anaplastic Lymphoma Kinase Gene Rearrangement (ALK-Positive NSCLC).

Funding Sources:

2012/3 - 2014/2 Synta Pharmaceuticals Inc. (USA)
Lung Cancer Clinical Trials Program
Total Funding - 100,000 (Canadian dollar)
Funding Competitive?: No

2012/2 - 2014/1
Principal Investigator

A Randomized, Phase IIB/III Study of Ganetespib (STA-9090) in Combination with Docetaxel Versus Docetaxel Alone in Subjects with Stage IIIb or IV Non-Small-Cell Lung Cancer, Contract
Clinical Research Project?: Yes

Funding Sources:

2011/10 - 2013/9 Synta Pharmaceuticals Inc. (USA)
Lung Cancer Clinical Trials Program
Total Funding - 75,000 (Canadian dollar)
Funding Competitive?: No

Principal Investigator : Roaslyn Juergens

2012/1 - 2013/12
Principal Investigator

A Multi-arm Phase I Study of BMS-936558 in Combination with Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, or Carboplatin/Paclitaxel in Subjects with Treatment-Naive Stage IIIB/IV NSC Lung Cancer, Contract
Clinical Research Project?: Yes

Funding Sources:

2012/1 - 2013/12 Bristol-Myers Squibb Canada Inc.
Phase I clinical Trial with BMS
Total Funding - 250,000 (Canadian dollar)
Funding Competitive?: No

Principal Investigator : Rosalyn Juergens

2011/1 - 2013/10
Principal Investigator

A Randomized, Double-Blind, Phase 2 Study of erlotinib (Tarceva®) in combination with OSI-906 or placebo in Chemonaive Patients with Advanced NSCLC with Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene, Contract
Clinical Research Project?: Yes

Funding Sources:

2011/10 - 2013/9 Astellas Pharma Canada, Inc.
Lung Cancer Clinical Trials Program
Total Funding - 86,430 (Canadian dollar)
Funding Competitive?: No

Completed [n=15]

2018/5 - 2020/4
Co-investigator

Biomarker study in conjunction with a phase I/II clinical trial of Debio-1143 and avelumab

Funding Sources:

BioCanRX
-
Total Funding - 100,000
Funding Competitive?: Yes

2016/6 - 2019/5
Principal Applicant

Oncolytic Virus Therapy in Cancer

Funding Sources:

2016/6 - 2019/5 BioCanRX
-
Total Funding - 120,000 (Canadian dollar)
Funding Competitive?: Yes

2015/4 - 2016/3
Principal Applicant

Study of MK-3475 (Pembrolizumab) Versus Platinum-based Chemotherapy for Participants With PD-L1-positive Advanced or Metastatic Non-small Cell Lung Cancer, Contract

Clinical Research Project?: Yes

Funding Sources:

2015/4 - 2016/3 Merck Frosst Canada Inc
Total Funding - 100,000 (Canadian dollar)
Funding Competitive?: No

2012/1 - 2015/8
Principal Applicant

A Multi-arm Phase I Study of BMS-936558 in Combination with Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, or Carboplatin/Paclitaxel in Subjects with Treatment-Naive Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC), Contract
Clinical Research Project?: Yes

Funding Sources:

2012/1 - 2015/8 Bristol-Myers Squibb Canada Inc.
Total Funding - 100,000 (Canadian dollar)
Funding Competitive?: No

2008/10 - 2013/9
Co-investigator

SPORE in Lung Cancer

Funding Sources:

2008/10 - 2013/9 National Institutes of Health (NIH) (USA)
Epigenetics in Lung Cancer - P50 CA058184
Total Funding - 886,450 (United States dollar)
Funding Competitive?: Yes

Principal Investigator : Baylin, Stephen

2008/3 - 2013/2
Co-investigator

Phase 1 clinical trials of new anti-cancer targeted therapies, Grant
Clinical Research Project?: Yes

Funding Sources:

2008/3 - 2013/2 National Institutes of Health (NIH) (USA)
U01 Program Grant - UO1 CA70095
Total Funding - 2,950,000 (United States dollar)
Funding Competitive?: Yes

Principal Investigator : Carducci, Michael

2009/10 - 2012/9
Co-investigator

Phase II single-arm trial comparing the use of FLT PET to standard computed tomography to assess the treatment response of neoadjuvant docetaxel and cisplatin in stage IB-IIIA resectable NSCLC
Clinical Research Project?: Yes

Funding Sources:

2009/10 - 2012/9 National Institutes of Health (NIH) (USA)
Molecular Imaging Group and ARRA - N01-CM-27018
Total Funding - 1,219,480 (United States dollar)
Funding Competitive?: Yes

Principal Investigator : Wahl, Richard

2008/8 - 2012/7
Co-investigator

CHFR Methylation for Predicting Taxane Sensitivity in Lung and Esophageal Cancer, Grant, Operating
Clinical Research Project?: Yes
Project Description: These studies, for both neoadjuvant and palliative treatments, will determine the clinical utility of CHFR methylation to predict sensitivity of lung and esophageal cancer to taxanes.

Funding Sources:

2008/8 - 2012/7 National Institutes of Health (NIH) (USA)
R33 CA127055-02
Total Funding - 660,000 (United States dollar)
Funding Competitive?: Yes

Principal Investigator : Herman, James

2007/7 - 2012/7
Principal Investigator

Targeting Epigenetic Changes in Metastatic Lung Cancer, Grant, Operating
Clinical Research Project?: Yes
Project Description: The major goal of this research proposal is to test the efficacy of combined epigenetic targeting in patients with advanced, recurrent NSCLC using 5AC and MS-275

Funding Sources:

2007/7 - 2012/6 Flight Attendant Medical Research Institute
Young Clinician Scientist Award
Total Funding - 500,000 (United States dollar)
Funding Competitive?: Yes

Principal Investigator : Rosalyn Juergens

2009/1 - 2010/12
Principal Investigator

Phase II Study of TAS-106 in Patients with Recurrent or Metastatic Head and Neck Cancer Refractory to Platinum Based Chemotherapy, Contract

Funding Sources:

2009/1 - 2010/12 Taiho Pharmaceutical Co., Ltd.
TAS 106
Total Funding - 254,094 (Canadian dollar)
Funding Competitive?: No

Principal Investigator : Rosalyn Juergens

2006/1 - 2010/12
Principal Investigator

Phase II Study in Operable Adenocarcinoma of the Esophagus to Measure Response Rate and Toxicity of Preoperative Combined Modality Paclitaxel, Cisplatin , ZD1839, and XRT Followed by Postop ZD1839, Contract

Funding Sources:

2006/1 - 2010/12 Astra Zeneca / US
Astra Zeneca Unsolicited Letter of Intent and Proposal
Total Funding - 250,000 (Canadian dollar)
Funding Competitive?: No

Principal Investigator : Rosalyn Juergens

2008/11 - 2010/10
Principal Investigator

A Phase I Dose-escalation Study of OSI-906 and Erlotinib in Patients with Advanced Solid Tumors, Contract

Funding Sources:

2008/11 - 2010/10 OSI Pharmaceuticals, Inc.
Phase I Clincial Trial with OSI
Total Funding - 320,912 (Canadian dollar)
Funding Competitive?: No

Principal Investigator : Rosalyn Juergens

2008/7 - 2010/7
Principal Investigator

Epigenetics in Lung Cancer, Fellowship

Funding Sources:

2008/7 - 2010/7 National Cancer Institute (USA)
Lung Cancer SPORE Career Development Awardee
Total Funding - 177,290 (United States dollar)
Funding Competitive?: Yes

2005/7 - 2010/6
Principal Investigator

Epigenetics in Lung Cancer

Funding Sources:

2005/7 - 2010/6 National Institutes of Health (NIH) (USA)
NIH Loan Repayment Grant Program
Total Funding - 240,000 (United States dollar)
Funding Competitive?: Yes

Principal Investigator : Rosalyn Juergens

2007/5 - 2010/4
Co-investigator

Phase I/II Study of MS-275 and 5-Azacytidine in Patients with Advanced Non-Small Cell Lung Cancer, Grant, Operating
Clinical Research Project?: Yes
Project Description: The major goal of this research proposal is to assess the safety, tolerability, pharmacokinetics, and efficacy of MS-275 and 5-Azacytidine in lung cancer patients.

Funding Sources:

2007/5 - 2010/4 National Institutes of Health (NIH) (USA)
R21 - 1R21 CA126265-01A1
Total Funding - 500,000 (United States dollar)
Funding Competitive?: Yes

Principal Investigator : Rudin, Charles

[n=]

2024/1 - 2025/12 , Grant

Courses Taught

2014/07/02 - 2016/06/01 Supervisor, Oncology, McMaster University
Course Title: Interviewing, Examination, and Reasoning (half day)
Number of Students: 5
Lecture Hours Per Week: 5

Student/Postdoctoral Supervision

Post-doctorate [n=13]

Co-Supervisor Safwan Baksh (In Progress) , McMaster University
Student Degree Start Date: 2018/9
Project Description: Supervision of writing up case report in ALK + NSCLC

Co-Supervisor	Aziz Abdul Al Farsi (Completed) , McMaster University Student Degree Start Date: 2015/7 Student Degree Received Date: 2017/6 Project Description: Co mentoring during Lung Cancer Clinical Fellowship Member of Masters of Health Sciences Thesis Committee
2021/7 - 2023/6 Principal Supervisor	Yuchen Li, McMaster University Thesis/Project Title: Quality improvement in clinical trials conduct Present Position: Medical Oncology Resident
2020/7 Principal Supervisor	Courtney Coschi, McMaster University Thesis/Project Title: Impact of translocation panel testing for never smokers with lung cancer in Hamilton, Ontario Present Position: Medical Oncology Resident
2018/10 - 2022/6 Principal Supervisor	Michaela Febbraro (Completed) , McMaster University Student Degree Start Date: 2018/10 Student Degree Received Date: 2022/6 Thesis/Project Title: Implementation of clinical trials in rural Ontario Project Description: Supervision of Longitudinal Clinic Present Position: Medical Oncology Resident / Fellow
2018/7 - 2020/6 Co-Supervisor	Samah AlRehaily (In Progress) , McMaster University Student Degree Start Date: 2018/7 Thesis/Project Title: Immunotherapy in Stage III NSCLC Project Description: Evaluation of appropriate use of octreotide scans in LHIN 4 Ontario Co-supervision of clinical fellowship Present Position: Clinical Fellow
2017/7 - 2019/1 Co-Supervisor	Ying Wang (In Progress) , McMaster Univeristy Student Degree Start Date: 2017/7 Thesis/Project Title: Implementation of PD-L1 testing in Hamilton, Ontario including validation of cytology for assessment of PD-L1 status Project Description: Biomarker assessment in immunotherapy in NSCLC Present Position: Assistant Professor
2016/7 - 2017/6 Co-Supervisor	Mohammed Al-Garni (Completed) , McMaster University Student Degree Start Date: 2016/7 Student Degree Received Date: 2017/6 Thesis/Project Title: Clinical fellowship in GI malignancies Project Description: Clinical fellowship co-supervisor Present Position: Assistant Professor - Saudi Arabia
2014/10 - 2015/6 Principal Supervisor	Paul Barnfield (Completed) , McMaster University Student Degree Start Date: 2014/7 Student Degree Received Date: 2016/6 Thesis/Project Title: Next generation sequencing in non-small cell lung cancer Project Description: Economic analysis of multiplex testing in comparison to individual molecular testing in non-squamous non-small cell lung cancer Present Position: Assistant Professor
2012/10 - 2013/6 Principal Supervisor	Brian Healy (Completed) , McMaster University Student Degree Start Date: 2013/7 Student Canadian Residency Status: Canadian Citizen Project Description: Medical Oncology Longitudinal Clinic Supervision

2011/9 - 2012/11
Principal Supervisor
Vandermeer Rachel (Completed) , McMaster University
Student Degree Start Date: 2012/4
Student Degree Received Date: 2013/6
Student Canadian Residency Status: Canadian Citizen
Thesis/Project Title: Clinical supervisor for lung and esophageal cancer. Project on management of locally advanced esophageal cancer.
Project Description: Randomized Trial of Chemotherapy followed by brachytherapy versus combined chemoradiotherapy in resectable esophageal cancer
Present Position: Adjunct Assistant Professor

2009/9 - 2011/6
Co-Supervisor
Roisin Connolly, (Completed) , Johns Hopkins Univ.
Student Degree Start Date: 2009/7
Student Canadian Residency Status: Not Applicable
Project Description: Double Epigentic Therapy in Breast Cancer
Present Position: Assistant Professor

2009/7 - 2011/6
Co-Supervisor
John Wrangle (Completed) , Johns Hopkins Univ.
Student Degree Start Date: 2009/7
Student Canadian Residency Status: Not Applicable
Project Description: CHFR directed therapy in esophageal cancer
Present Position: Fellow

Staff Supervision

Mentoring Activities

2015/1
Internal Medicine Resident Mentor, McMaster University
Number of Mentorees: 1

Journal Review Activities

Reviewer,The Open Clinical Cancer Journal
Number of Works Reviewed / Refereed: 1

Reviewer,Clinical Cancer Research
Number of Works Reviewed / Refereed: 1

Reviewer,Asian Pacific Journal of Oncology
Number of Works Reviewed / Refereed: 1

2011/9
Reviewer,Cancer Biology and Therapy
Number of Works Reviewed / Refereed: 1

2010/8
Reviewer,British Journal of Oncology
Number of Works Reviewed / Refereed: 2

2009/6
Reviewer,Biomed Central - Cancer
Number of Works Reviewed / Refereed: 1

2009/2
Reviewer,Journal of Clinical Oncology
Number of Works Reviewed / Refereed: 2

2007/11 - 2011/12
Reviewer,Annals of Surgical Oncology
Number of Works Reviewed / Refereed: 4

2007/1 - 2009/3 Reviewer,American Journal of Medicine
Number of Works Reviewed / Refereed: 2

Conference Review Activities

2013/2 - 2013/4 Abstract Reviewer, 8th Annual Ontario Thoracic Cancer Conference, Blind, McMaster University
Number of Works Reviewed / Refereed: 26

Research Funding Application Assessment Activities

2013/5 - 2013/5 Committee Member, Juravinski Cancer Centre Foundation Spring Grant Review Panel, Funder, Academic Reviewer, Juravinski Cancer Centre Foundation
Number of Applications Assessed: 6

2009/6 - 2009/7 Committee Member, Department of Defense Grant Review Study Section, Funder, Academic Reviewer, Department of Defense
Number of Applications Assessed: 4

Event Participation

Invited Speaker, Shanghai Oriental Respiratory Forum, Conference, 2008/12 - 2008/12

Invited Speaker, 8th Annual Ontario Thoracic Cancer Conference, Conference, 2013/4 - 2013/4

Attendee, 10th Annual Targeted Therapies in the Treatment of Lung Cancer, Conference, 2010/2 - 2010/2
Overview of all agents in development for treatment of lung cancer

Attendee, New Investigator Workshop, Workshop, 2011/11 - 2011/11

Oral and poster presenter, Johns Hopkins Workshop on Clinical Targeting of Epigenetic Changes in Cancer Therapeutics, Workshop, 2011/1 - 2011/1

Invited Speaker, 13th Annual Targeted Therapies in the Treatment of Lung Cancer, Conference, 2013/2 - 2013/2

Attendee, Accelerating Anticancer Agent Development and Validation Workshop, Workshop, 2009/6 - 2009/6
Intensive and interactive workshop in how to design effective strategies- from clinical trial initiatives, to enabling trials, to pivotal efficacy trials - leading to the development of new anticancer and prevention agents.

Invited Speaker, 12th Annual Targeted Therapies in the Treatment of Lung Cancer, Conference, 2012/2 - 2012/2

Attendee, Johns Hopkins Workshop on Clinical Targeting of Epigenetic Changes in Cancer Therapeutics, Workshop, 2007/1 - 2007/1

Invited Speaker, 11th Annual Targeted Therapies in the Treatment of Lung Cancer, Conference, 2011/2 - 2011/2

Community and Volunteer Activities

2018/10 Physician Champion for Illuminight, Hamilton Health Sciences Corporation
Physician Champion for Fundraising Event

2017/11	Speaker at Lung Cancer Patient Forum, Lung Cancer Canada
2017/11	Patient / Caregiver Education Speaker, Wellwood
2016/11	Speaker at Lung Cancer Patient and Caregiver Summit, Lung Cancer Canada
2016/6	Executive Board Member, Lung Cancer Canada
2016/6	Chair of the Medical Advisory Committee, Lung Cancer Canada I have been invited to be a member of the Lung Cancer Canada Medical Advisory Panel
2014/6	Co-chair of Program Committee, Lung Cancer Canada 1) Develop and manage programs, projects and events; 2)Develop and manage the publication and distribution of newsletters, information sheets and other publications;

International Collaboration Activities

2011/1	Collaborator, United States of America Ongoing collaboration with epigenetic research projects on AACR Stand Up to Cancer Grant

Committee Memberships

2018/3	Committee Member, Esophageal Diagnostic Pathway Panel, Cancer Care Ontario
2017/9	Committee Member, Clinical Accelerator Scientific Leadership Committee, Cancer Research Institute
2017/3	Chair, Department of Clinical Trials Executive Committee, Juravinski Cancer Centre
2016/6	Chair, Medical Advisory Committee, Lung Cancer Canada, Lung Cancer Canada
2015/7	Committee Member, Medical Oncology Residency Education Committee, Juravinski Cancer Centre
2015/6	Committee Member, Disease Site Team Council, Juravinski Cancer Centre
2013/2	Chair, Lung Disease Site Team, Juravinski Cancer Centre
2011/1 - 2016/12	Committee Member, Translational Research Team - Management Committee, McMaster University
2009/7 - 2010/12	Committee Member, Johns Hopkins SKCC Education Committee, Johns Hopkins University
2009/7 - 2010/12	Co-chair, Visiting Professor Committee, Johns Hopkins University
2007/7 - 2010/12	Committee Member, U01 Internal Committee Member, Johns Hopkins University
2005/7 - 2010/12	Committee Member, Oncology Fellowship Advisory Committee, Johns Hopkins University
2004/7 - 2010/12	Committee Member, Oncology Critical Care Committee, Johns Hopkins Medical Institutions
2006/7 - 2007/12	Committee Member, Oncology Outpatient Department Advisory Committee, Johns Hopkins University
2003/7 - 2004/6	Committee Member, Core Committee on Physician Order Entry, Johns Hopkins University Role: Oncology fellowship representative
2002/7 - 2003/6	Committee Member, Performance Improvement Committee, Johns Hopkins Hospital

2002/ - 2003/	Committee Member, Steering Committee for Computerized Clinical Information Systems, Johns Hopkins Hospital Role: Medicine Residency Program Representative
2001/ - 2003/	Committee Member, Johns Hopkins Hospital Laboratory Advisory Committee, Johns Hopkins Hospital Role: Medicine Residency Program Representative

Other Memberships

2011/9	Core Member, Escarpment Cancer Research Institute

Presentations

1. (2020). Update on ATL-001. International Association for the Study of Lung Cancer: Targeted Therapy in Lung Cancer Meeting, United States of America
   Main Audience: Researcher
   Invited?: Yes, Keynote?: No
2. (2020). Strategies for Treating Patients with Resistance to Immunotherapy. American Society of Clinical Oncology Annual Education Meeting, United States of America
   Main Audience: Knowledge User
   Invited?: Yes, Keynote?: No
3. Matthew Hellman and Solange Peters. (2018). The New Era of Immune Therapy in Lung Cancer. World Congress on Lung Cancer, Toronto, Canada
   Main Audience: Knowledge User
   Invited?: Yes
4. (2018). Immune Checkpoint and Chemotherapy Combinations. World Congress on Lung Cancer, Toronto, Canada
   Main Audience: Knowledge User
   Invited?: Yes
5. (2018). New Era in Management of NSCLC. Employers Cancer Care Conference, Toronto, Canada
   Main Audience: General Public
   Invited?: Yes
6. (2018). From Bedside to Bench and Back: The Story of Immunotherapy in Oncology. Juravinski Cancer Centre Student Research Day, Canada
   Main Audience: Researcher
   Invited?: Yes, Keynote?: Yes
7. (2018). Update on Immunotherapy in Lung Cancer. Immuno-Oncology Summit, Toronto, Canada
   Main Audience: Knowledge User
   Invited?: Yes
8. (2018). Recognition and Management of Immuno-oncology Toxicities. Canadian Cancer Trials Group, Toronto, Canada
   Main Audience: Knowledge User
   Invited?: Yes
9. (2018). First Line Immunotherapy in Non-Small Cell Lung Cancer. World Congress on Lung Cancer, Canada
   Main Audience: Knowledge User
   Invited?: Yes, Keynote?: No

10. (2018). Patients and Physicians as Partners. Department of Oncology Student Research Day, Hamilton, Canada
    Main Audience: Knowledge User
    Invited?: Yes
11. (2018). First Line Immunotherapy in Lung Cancer. Best of Lung Cancer, Toronto, Canada
    Main Audience: Knowledge User
    Invited?: Yes
12. (2017). Impact of Molecular testing in NSCLC. Precision Medicine Workshop, Toronto, Canada
    Main Audience: Knowledge User
    Invited?: Yes
13. (2017). Biomarkers to Guide Immuno-oncology Use. Immuno-oncology Summit, Toronto, Canada
    Main Audience: Knowledge User
    Invited?: Yes
14. (2017). Pseudoprogression in Immuno-oncology. National Consensus Meeting, Ottawa, Canada
    Main Audience: Knowledge User
    Invited?: Yes
15. (2017). PD-L1 Inhibition in Non-Small Cell Lung Cancer. World Congress on Lung Cancer, Vienna, Austria
    Main Audience: Knowledge User
    Invited?: Yes
16. (2017). Recognition and Management of Immuno-oncology Toxicities. C17 Annual Meeting, Vancouver, Canada
    Main Audience: Knowledge User
    Invited?: Yes
17. (2017). Innovations in Lung Cancer Treatments and Access to Therapies. Lung Cancer Canada Stakeholder Briefing, Vancouver, Canada
    Main Audience: Decision Maker
    Invited?: Yes
18. (2017). Immuno-oncology in Lung Cancer. Immuno-oncology Summit, Toronto, Canada
    Main Audience: Knowledge User
    Invited?: Yes
19. (2017). Systemic Therapy in NSCLC - A New Hope. Lung Cancer Canada Patient Summit, Vancouver, Canada
    Main Audience: General Public
    Invited?: Yes
20. (2017). Immuno-oncology in GI Cancers. Immuno-oncology Summit, Toronto, Canada
    Main Audience: Knowledge User
    Invited?: Yes
21. (2017). Management of Stage III NSCLC. Health Canada Presentation, Ottawa, Canada
    Main Audience: Decision Maker
    Invited?: Yes
22. Ellis, P. (2016). Developments in immuno-oncology: What does an internist need to know about releasing the brakes in the immune system?. McMaster University Internal Medicine Grand Rounds, Hamilton, Canada
    Main Audience: Knowledge User
    Invited?: Yes

23. (2016). Immunotherapy in Lung Cancer. British Columbia Cancer Agency Province Wide Rounds, Vancouver, Canada
Main Audience: Knowledge User
Invited?: Yes

24. (2016). Immunotherapy in Cancer. St. Michael's Annual Oncology Lectureship, Toronto, Canada
Main Audience: Knowledge User
Invited?: Yes

25. (2016). Basics in Immuno-Oncology for GI Malignancies. 5th Multidisciplinary Annual Gastrointestinal Cancer Update, Toronto, Canada
Main Audience: Knowledge User
Invited?: Yes

26. (2016). Immunotherapy in Cancer. Juravinski Hospital and Cancer Centre Oncology Inpatient Ward Education Day, Hamilton, Canada
Main Audience: General Public
Invited?: Yes

27. (2016). Update on Lung Cancer. Canadian Conference on Community Oncology, Whistler, Canada
Main Audience: Knowledge User

28. (2016). From Medical School to Oncology: The Long and Winding Road. Student Research Day, Winnipeg, Canada
Main Audience: Researcher
Invited?: Yes, Keynote?: Yes

29. (2016). Management of Gastric Cancer. Grand River Cancer Centre Regional Oncology Rounds, Kitchener, Canada
Main Audience: Knowledge User
Invited?: Yes

30. (2016). Biology of Stem Cells in Lung Cancer. 15th Annual Targeted Therapies of the Treatment of Lung Cancer., Santa Monica, United States of America
Main Audience: Researcher
Invited?: Yes

31. (2016). ASCO Lung Cancer Update. Regional Oncology Rounds, Hamilton, Canada
Main Audience: Knowledge User

32. (2016). Pathology Implications of Recent Treatment Advances in NSCLC. Hamilton Regional Pathology Meeting, Hamilton, Canada
Main Audience: Knowledge User
Invited?: Yes

33. (2016). Immunotherapy in Lung Cancer. Oncology Grand Rounds, Halifax, Canada
Main Audience: Knowledge User

34. (2016). Immunotherapy in GI Malignancies. LHIN 4 GI Symposium, Hamilton, Canada
Main Audience: Knowledge User
Invited?: Yes

35. Garth Nicholas, John Goffin, Scott Andrew Laurie, Andrew Robinson, Glenwood Goss, Neil Reaume, Mihaela Mates, Paul Wheately-Price, Peter Ellis, Anna Tomiak, Richard Gregg. (2016). A phase Ib study of selumetinib in patients with previously untreated advanced/metastatic NSCLC who are receiving standard chemotherapy regimen: trial IND215 of the NCIC Clinical Trials Group. ASCO, Chicago, United States of America
Main Audience: Researcher
Invited?: Yes, Competitive?: Yes

36. (2016). Immunotherapy in Lung Cancer Cancer Care. Manitoba Provincial Oncology Rounds, Winnipeg, Canada
Main Audience: Knowledge User
Invited?: Yes

37. (2016). DNA Repair and Epigenetics in Cancer. Molecular Oncology for REsidents (MORE) Retreat, Hamilton, Canada
Main Audience: Knowledge User
Invited?: Yes

38. (2016). Immunotherapy in Lung Cancer. AMHOQ Annual Meeting, Quebec, Canada
Main Audience: Knowledge User
Invited?: Yes

39. (2016). Systemic Therapy in Gastric Cancer. Canadian Conference on Community Oncology, Whistler, Canada
Main Audience: Knowledge User

40. (2016). Immunotherapy in Lung Cancer. Cancer Care Manitoba Provincial Oncology Rounds, Winnipeg, Canada
Main Audience: Knowledge User
Invited?: Yes

41. (2016). Immunotherapy in Cancer. Central LHIN Humber River Oncology Nursing Day, Toronto, Canada
Main Audience: Knowledge User
Invited?: Yes

42. (2016). Pulmonary Adenocarcinomas: An Update. Cancer Care Ontario Fall Webinar, Toronto, Canada
Main Audience: Knowledge User
Invited?: Yes

43. (2016). Lung Cancer: Recent Advances, Practical Information and Recommendations. Immuno-Oncology Update, Toronto, Canada
Main Audience: Knowledge User
Invited?: Yes

44. (2016). Immunotherapy in Lung Cancer Canadian Oncology Resident Education (CORE). Canadian Lung Cancer Conference, Canada
Main Audience: Knowledge User

45. (2015). Immunotherapy in Lung Cancer. Juravinski Cancer Centre Regional Oncology Rounds, Hamilton, Canada
Main Audience: Knowledge User
Invited?: Yes

46. (2015). Immunotherapy in Lung Cancer, Where are we now?. Canadian Lung Cancer Conference, Vancouver, Canada
Main Audience: Knowledge User
Invited?: Yes

47. (2015). Immunotherapy in Lung Cancer. Oncology Grand Rounds - Grand River Regional Cancer Centre, Kitchener, Canada
Main Audience: Knowledge User

48. (2015). Basics in Immuno-Oncology: From Bench to Bedside. Atlantic Canada Immuno-Oncology Symposium, Moncton, Canada
Main Audience: Knowledge User
Invited?: Yes

49. (2015). Chair of New Kinase Targets Session. World Conference on Lung Cancer, Denver, United States of America
Main Audience: Researcher
Invited?: Yes

50. (2015). Lung Cancer Immunotherapy. The Landscape in Canada Best of Lung Cancer Symposium, Toronto, Canada
Main Audience: Knowledge User
Invited?: Yes

51. (2015). Immunotherapy in Lung Cancer. Canadian Cancer Research Conference, Montreal, Canada
Main Audience: Knowledge User

52. (2015). Future of Immunotherapy in Lung Cancer. Canadian Lung Cancer Conference, Canada
Main Audience: Knowledge User
Invited?: Yes, Keynote?: No

53. (2015). Chair of ALK and HSP90 Session on Targeted Therapies in Lung Cancer 15th Annual Targeted Therapies in the Treatment of Lung Cancer. 15th Annual Targeted Therapies in the Treatment of Lung Cancer, Santa Monica, United States of America
Main Audience: Researcher
Invited?: Yes

54. (2015). Immunotherapy: A new pillar of cancer treatment. Canadian Oncology Advocacy Meeting, Montreal, Canada
Main Audience: Knowledge User
Invited?: Yes

55. (2015). Immunotherapy in Lung Cancer. Ontario Thoracic Cancer Conference, Niagara-on-the-lake, Canada
Main Audience: Knowledge User
Invited?: Yes

56. Massey, N. (2015). Targeting the PD-1 / PD-L1 Axis: How Immunotherapies are Changing the Treatment of Non-Small Cell Lung Cancer. Canadian Association of Nursing in Oncology Annual Meeting, Toronto, Canada
Main Audience: Knowledge User
Invited?: Yes

57. (2014). Insulin-like growth factor inhibitors in lung cancer therapy. 14th Annual Targeted Therapies of the Treatment of Lung Cancer, Santa Monica, United States of America
Main Audience: Researcher
Invited?: Yes

58. (2014). Epigenetic Therapy in Lung Cancer. 14th Annual Targeted Therapies in the Treatment of Lung Cancer, Santa Monica, United States of America
Main Audience: Researcher
Invited?: Yes

59. (2014). Double Epigenetic Therapy. 14th Annual Targeted Therapies of the Treatment of Lung Cancer, Santa Monica, United States of America
Main Audience: Researcher
Invited?: Yes

60. (2014). Update on Lung Cancer. Juravinski Cancer Centre Chemotherapy Suite Nurses Education Rounds, Hamilton, Canada
Main Audience: Knowledge User
Invited?: Yes

61. (2014). Chemoradiation in esophageal cancer. Regional Oncology Rounds, Juravinski Cancer Centre, Hamilton, Canada
Main Audience: Knowledge User
Invited?: Yes

62. (2014). OSI-906 in Lung Cancer. 14th Annual Targeted Therapies in the Treatment of Lung Cancer, Santa Monica, United States of America
Main Audience: Researcher
Invited?: Yes

63. (2013). Targeted Therapies in Squamous Non-Small Cell Lung Cancer. 8th Annual Ontario Thoracic Cancer Conference, Niagara-on-the-Lake, Canada
Main Audience: Knowledge User
Invited?: Yes, Keynote?: No

64. (2013). Novel Therapies for Squamous Cell Lung Cancer. 8th Annual Ontario Thoracic Cancer Conference, Niagara-on-the-lake, Canada
Main Audience: Knowledge User
Invited?: Yes

65. Jonathan Bramson, PhD. (2012). Harnessing the Immune System in Cancer Treatment. Demystifying Medicine, McMaster University, Hamilton, Canada
Main Audience: Knowledge User
Invited?: Yes

66. (2011). Analysis of a Phase II trial of 5-azacitidine(5AC) and entinostat (SNDX-275) in relapsed advanced lung cancer.5th Biennial Workshop on the Clinical Translation of Epigenetics in Cancer Therapy., San Diego, CA, United States of America
Main Audience: Researcher
Invited?: Yes, Keynote?: No

Broadcast Interviews

2017/11/12	Lung Cancer in Never Smokers, The National, CTV
2017/01/17	Immunotherapy in Cancer, Hamilton Spectator

Publications

Journal Articles

1. Rupp M, Fanton-Aita F, Snow S, Wheatley-Price P, Melosky B, Juergens RA, Chu Q, Blais N, Banerji S, Ng R, Khoudigian S, Sharma A, On PV, Liu G. (2023). Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience.Curr Oncol.30(7): 6559-6574.
http://dx.doi.org/10.3390/curroncol30070481.
Co-Author
Published,
Refereed?: Yes, Open Access?: No

2. Melosky BL, Leighl NB, Dawe D, Blais N, Wheatley-Price PF, Chu QS, Juergens RA, Ellis PM, Sun A, Schellenberg D, Ionescu DN, Cheema PK. (2023). Canadian Consensus Recommendations on the Management of Extensive-Stage Small-Cell Lung Cancer.Curr Oncol.30(7): 6289-6315.
http://dx.doi.org/10.3390/curroncol30070465.
Published,
Refereed?: Yes, Open Access?: No

3. Coschi CH, Juergens RA. (2023). Overcoming Resistance Mechanisms to Immune Checkpoint Inhibitors: Leveraging the Anti-Tumor Immune Response.Curr Oncol.31(1): 1-23.
http://dx.doi.org/10.3390/curroncol31010001
Last Author
Published,
Refereed?: Yes, Open Access?: No
Number of Contributors: 2

4. Esfahanian N, Chan SWS, Zhan LJ, Brown MC, Khan K, Lee J, Balaratnam K, Yan E, Parker J, Garcia-Pardo M, Barghout SH, Eng L, Bradbury PA, Shepherd FA, Leighl NB, Sacher AG, Snow S, Juergens R, Liu G. (2023). Presentation and outcomes of KRASG12C mutant non-small cell lung cancer patients with stage IV disease at diagnosis (de novo) versus at recurrence.Presentation and outcomes of KRASG12C mutant non-small cell lung cancer patients with stage IV disease at diagnosis (de novo) versus at recurrence.37(100774)
http://dx.doi.org/10.1016/j.ctarc.2023.100774
Co-Author
Published,
Refereed?: Yes, Open Access?: No
Number of Contributors: 19

5. Febbraro M, Kazemi G, Juergens R, Pond GR. (2023). Trainee Evaluations of Preparedness for Clinical Trials in Medical Oncology-A National Questionnaire.Curr Oncol.30(8): 7627-7637.
http://dx.doi.org/10.3390/curroncol30080553
Co-Author
Published,
Refereed?: Yes, Open Access?: No

6. Anagnostou V, Ho C, Nicholas G, Juergens RA, Sacher A, Fung AS, Wheatley-Price P, Laurie SA, Levy B, Brahmer JR, Balan A, Niknafs N, Avrutin E, Zhu L, Sausen M, Bradbury PA, O'Donnell-Tormey J, Gaudreau PO, Ding K, Dancey J. (2023). ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results.Nat Med.29(10): 2559-2569..
http://dx.doi.org/10.1038/s41591-023-02598-9
Published,
Refereed?: Yes, Open Access?: No

7. Catenacci DV, Kang YK, Uronis HE, Lee KW, Ng MC, Enzinger PC, Park SH, Gold PJ, Lacy J, Hochster HS, Oh SC, Kim YH, Marrone KA, Kelly RJ, Juergens RA, Kim JG, Alcindor T, Sym SJ, Song EK, Chee CE, Chao Y, Kim S, Oh DY, Yen J, Odegaard JI, Lagow E, Li D, Sun J, Kaminker P, Moore PA, Rosales MK, Park H. (2023). Circulating Tumor DNA as a Predictive Biomarker for Clinical Outcomes With Margetuximab and Pembrolizumab in Pretreated HER2-Positive Gastric/ Gastroesophageal Adenocarcinoma.Oncology. 37(4): 176-183..
http://dx.doi.org/10.46883/2023.25920992.
Co-Author
Published, Williston Park,
Refereed?: Yes, Open Access?: No

8. Chan SWS, Shukla R, Ramsay J, McWhirter E, Barnfield P, Juergens RA. (2023). Immune-Checkpoint Induced Skin Toxicity Masked as Squamous Cell Carcinoma: Case Report on Mimickers of Dermatological Toxicity with PD-1 Inhibition.Curr Oncol.30(5): 4527-4537.
http://dx.doi.org/10.3390/curroncol30050342.
Last Author
Published,
Refereed?: Yes, Open Access?: No

9. Sayeda S, Naqvi A, Begum H, Juergens RA, Finley C, Coschi CH, Cutz JC, Bonert M. (2023). Prevalence of Thyroid Transcription Factor-1 (TTF-1)-Negative Small Cell Carcinoma and Napsin A Positivity in Small Cell Carcinoma in a Cross-Sectional Study of Lung Core Biopsies.Cureus. 15(4): e37015. http://dx.doi.org/10.7759/cureus.37015
Co-Author
Published,
Refereed?: Yes, Open Access?: No

10. Cheema PK, Banerji SO, Blais N, Chu QS, Juergens RA, Leighl NB, Sacher A, Sheffield BS, Snow S, Vincent M, Wheatley-Price PF, Yip S, Melosky BL. (2023). Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC.Curr Oncol.30(7): 6473-6496. http://dx.doi.org/10.3390/curroncol30070476.
Co-Author
Published,
Refereed?: Yes, Open Access?: No

11. Li Y, Juergens RA, Finley C, Swaminath A. (2023). Current and Future Treatment Options in the Management of Stage III NSCLC.J Thorac Oncol.18(11): 1478-1491. http://dx.doi.org/10.1016/j.jtho.2023.08.011.
Co-Author,
Refereed?: Yes, Open Access?: No

12. Bonert M, Berzins A, Begum H, Schittenhelm J, Lu JQ, Juergens RA, Swaminath A, Cutz JC, Naqvi AH. (2023). Neuroanatomical location of brain metastases from solid tumours based on pathology: An analysis of 511 patients with a comparison to the provided clinical history.PLoS One.18(11): e0294154. http://dx.doi.org/10.1371/journal.pone.0294154.
Published,
Refereed?: Yes, Open Access?: No

13. Chu Q, Leighl NB, Surmont V, van Herpen C, Sibille A, Markman B, Clarke S, Juergens RA, Rivera MA, Andelkovic V, Rudin CM, Snow S, Kim DW, Sanatani M, Lin H, Sanghavi K, Tannenbaum-Dvir S, Basciano P, Lathers D, Urbanska K, Kollia G, He C, DiPiero A, Liu Y, Ready N. (2022). BMS-986012, an Anti-Fucosyl-GM1 Monoclonal Antibody as Monotherapy or in Combination With Nivolumab in Relapsed/ Refractory SCLC: Results From a First-in-Human Phase 1/2 Study.JTO Clin Res Rep.3(11): 100400. http://dx.doi.org/10.1016/j.jtocrr.2022.100400.
Published,
Refereed?: Yes, Open Access?: No

14. Ezeife DA, Spackman E, Juergens RA, Laskin JJ, Agulnik JS, Hao D, Laurie SA, Law JH, Le LW, Kiedrowski LA, Melosky B, Shepherd FA, Cohen V, Wheatley-Price P, Vandermeer R, Li JJ, Fernandes R, Shokoohi A, Lanman RB, Leighl NB. (2022). The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer.Ther Adv Med Oncol.14: 17588359221112696. http://dx.doi.org/10.1177/17588359221112696.
Co-Author
Published,
Refereed?: Yes, Open Access?: No

15. Husereau D, Sullivan T, Feilotter HE, Gomes MM, Juergens R, Sheffield BS, Kassam S, Stockley TL, Jacobs P. (2022). Optimizing the delivery of genetic and advanced diagnostic testing in the province of Ontario: challenges and implications for laboratory technology assessment and management in decentralized healthcare systems.J Med Econ.25(1): 993-1004.. http://dx.doi.org/10.1080/13696998.2022.2101807.
Published,
Refereed?: Yes, Open Access?: No

16. Lee Y, Samarasinghe Y, Lee MH, Thiru L, Shargall Y, Finley C, Hanna W, Levine O, Juergens R, Agzarian, J. (2022). Role of Adjuvant Therapy in Esophageal Cancer Patients After Neoadjuvant Therapy and Esophagectomy: A Systematic Review and Meta-analysis. . Annals of Surgery. 275(1): 91-98.
Published,
Refereed?: Yes, Open Access?: No

17. Febbraro M, Gheware A, Kennedy T, Jain D, de Moraes FY, Juergens R. (2022). Barriers to Access: Global Variability in Implementing Treatment Advances in Lung Cancer.Am Soc Clin Oncol Educ Book.42: 1-7.
Published,
Refereed?: Yes, Open Access?: No

18. Bonert M, Zafar U, Williams P, El-Shinnawy I, Juergens RA, Naqvi A, Cutz JC, Finley C, Major P, Kapoor A. (2022). Physician and Surgeon Communication Assessed via the Pathology Requisition in a Regional Laboratory Over Ten Years.Cureus.14(8): e27714.
http://dx.doi.org/10.7759/cureus.27714.
Published,

19. Ramadan S, Quan K, Schnarr K, Juergens RA, Hotte SJ, Mukherjee SD, Kapoor A, Meyers BM, Swaminath A. (2022). Impact of stereotactic body radiotherapy (SBRT) in oligoprogressive metastatic disease.Acta Oncol.61(6): 705-713..
http://dx.doi.org/10.1080/0284186X.2022.2063067
Published,
Refereed?: Yes, Open Access?: No

20. Melosky B, Cheema P, Juergens RA, Leighl NB, Liu G, Wheatley-Price P, Sacher A, Snow S, Tsao MS, McLeod D, Chu Q. (2021). The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer. . Ther Adv Med Oncol.11: 1.
Published,
Refereed?: Yes, Open Access?: No

21. Melosky B, Wheatley-Price P, Juergens RA, Sacher A, Leighl NB, Tsao MS, Cheema P, Snow S, Liu G, Card PB, Chu Q. (2021). The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer.Lung Cancer. 160: 136-151.
Published,
Refereed?: Yes, Open Access?: No

22. Ortega C, Wong RKS, Schaefferkoetter J, Veit-Haibach P, Myrehaug S, Juergens R, Laidley D, Anconina R, Liu A, Metser U. (2021). Quantitative 68Ga-DOTATATE PET/CT Parameters for the Prediction of Therapy Response in Patients with Progressive Metastatic Neuroendocrine Tumors Treated with 177Lu-DOTATATE.Journal of Nuclear Medicine. 62(10): 1406-1414.
Published,
Refereed?: Yes, Open Access?: No

23. Seow H, Tanuseputro P, Barbera L, Earle CC, Guthrie DM, Isenberg SR, Juergens RA, Myers J, Brouwers M, Tibebu S, Sutradhar R. (2021). Development and validation of a prediction model of poor performance status and severe symptoms over time in cancer patients (PROVIEW+).Palliative Medicine. 35(9): 1713-1723.
Published,
Refereed?: Yes, Open Access?: No

24. Bonert M, Zafar U, Maung R, El-Shinnawy I, Kak I, Cutz JC, Naqvi A, Juergens RA, Finley C, Salama S, Major P, Kapoor A. (2021). Evolution of anatomic pathology workload from 2011 to 2019 assessed in a regional hospital laboratory via 574,093 pathology reports.PLoS One. 16(6): 1.
Published,
Refereed?: Yes, Open Access?: No

25. Coschi CH, Juergens RA. (2021). The Price of Success: Immune-Related Adverse Events from Immunotherapy in Lung Cancer.Current Oncology. 28(6): 4392-4407.
Published,
Refereed?: Yes, Open Access?: No

26. Debieuvre D, Juergens RA, Asselain B, Audigier-Valette C, Auliac JB, Barlesi F, Benoit N, Bombaron P, Butts CA, Dixmier A, Gröschel A, Gutz S, Labbé C, Moro-Sibilot D, Pérol M, Raspaud C, Schumann C, Juarez-Garcia A, Lakhdari K, Pettersson F, Penrod JR, Reynaud D, Waldenberger D, Allan V, Sebastian M. (2021). Two-year survival with nivolumab in previously treated advanced non-small-cell lung cancer: A real-world pooled analysis of patients from France, Germany, and Canada.Lung Cancer. 157: 40-47.
Published,
Refereed?: Yes, Open Access?: No

27. Melosky B, Cheema P, Juergens RA, Leighl NB, Liu G, Wheatley-Price P, Sacher A, Snow S, Tsao MS, McLeod D, Chu Q. (2021). The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer.Ther Adv Med Oncol.13: 17588359211056306.
http://dx.doi.org/10.1177/17588359211056306.
Published,
Refereed?: Yes, Open Access?: No

28. Cheema PK, Banerji SO, Blais N, Chu QS, Desmeules P, Juergens RA, Leighl NB, Sheffield BS, Wheatley-Price PF, Melosky BL. (2021). Canadian Consensus Recommendations on the Management of MET-Altered NSCLC.Curr Oncol.28(6): 4552-4576..
http://dx.doi.org/10.3390/curroncol28060386.
Published,
Refereed?: Yes, Open Access?: No

29. Melosky B , Banerji S , Blais N , Chu Q , Juergens R , Leighl NB , Liu G , Cheema P. (2020). Canadian consensus: a new systemic treatment algorithm for advanced *EGFR*- mutated non-small-cell lung cancer. Current oncology. 27(2): e146-e155.
Published,

30. Nehra J , Bradbury PA , Ellis PM , Laskin J , Kollmannsberger C , Hao D , Juergens RA , Goss G , Wheatley-Price P , Hotte SJ , Gelmon K , Tinker AV , Brown-Walker P , Gauthier I , Tu D , Song X , Khan A , Seymour L , Smoragiewicz M. (2020). A Canadian cancer trials group phase IB study of durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) given concurrently or sequentially in patients with advanced, incurable solid malignancies.Investigational new drugs. 38(5): 1442-1447.
Published,

31. Melosky B , Cheema PK , Brade A , McLeod D , Liu G , Price PW , Jao K , Schellenberg DD , Juergens R , Leighl N , Chu Q. (2020). Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung Cancer.The oncologist. 25(1): 64-77.
Published,

32. Juergens RA , Hao D , Ellis PM , Tu D , Mates M , Kollmannsberger C , Bradbury PA , Tehfe M , Wheatley-Price P , Robinson A , Bebb G , Laskin J , Goffin J , Hilton J , Tomiak A , Hotte S , Goss GD , Brown-Walker P , Sun X , Tsao MS , Cabanero M , Gauthier I , Song X , Dennis PA , Seymour LK , Smoragiewicz M , Laurie SA. (2020). A phase IB study of durvalumab with or without tremelimumab and platinum-doublet chemotherapy in advanced solid tumours: Canadian Cancer Trials Group Study IND226.Lung cancer (Amsterdam, Netherlands). 143: 1-11.
Published,

33. Dawe DE , Harlos CH , Juergens RA. (2020). Immuno-oncology-the new paradigm of lung cancer treatment.Current oncology (Toronto, Ont.). 27(Suppl 2): S78-S86.
Published,

34. Catenacci DVT , Kang YK , Park H , Uronis HE , Lee KW , Ng MCH , Enzinger PC , Park SH , Gold PJ , Lacy J , Hochster HS , Oh SC , Kim YH , Marrone KA , Kelly RJ , Juergens RA , Kim JG , Bendell JC , Alcindor T , Sym SJ , Song EK , Chee CE , Chao Y , Kim S , Lockhart AC , Knutson KL , Yen J , Franovic A , Nordstrom JL , Li D , Wigginton J , Davidson-Moncada JK , Rosales MK , Bang YJ , CP-MGAH22-5 Study Group. (2020). Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial.The Lancet. Oncology. 21(8): 1066-1076.
Published,

35. Lu Z , Zou J , Li S , Topper MJ , Tao Y , Zhang H , Jiao X , Xie W , Kong X , Vaz M , Li H , Cai Y , Xia L , Huang P , Rodgers K , Lee B , Riemer JB , Day CP , Yen RC , Cui Y , Wang Y , Wang Y , Zhang W , Easwaran H , Hulbert A , Kim K , Juergens RA , Yang SC , Battafarano RJ , Bush EL , Broderick SR , Cattaneo SM , Brahmer JR , Rudin CM , Wrangle J , Mei Y , Kim YJ , Zhang B , Wang KK , Forde PM , Margolick JB , Nelkin BD , Zahnow CA , Pardoll DM , Housseau F , Baylin SB , Shen L , Brock MV. (2020). Epigenetic therapy inhibits metastases by disrupting premetastatic niches.Nature. 579(7798): 284-290.
Published,

36. Colomer-Lahiguera S , Bryant-Lukosius D , Rietkoetter S , Martelli L , Ribi K , Fitzpatrick-Lewis D , Sherifali D , Orcurto A , Juergens R , Eicher M. (2020). Patient-reported outcome instruments used in immune-checkpoint inhibitor clinical trials in oncology: a systematic review.Journal of patient-reported outcomes. 4(1): 58.
Published,

37. Melosky B , Juergens R , Hirsh V , McLeod D , Leighl N , Tsao MS , Card PB , Chu Q. (2020). Amplifying Outcomes: Checkpoint Inhibitor Combinations in First-Line Non-Small Cell Lung Cancer.The oncologist. 25(1): 64-77.
Published,

38. Seow H , Tanuseputro P , Barbera L , Earle C , Guthrie D , Isenberg S , Juergens R , Myers J , Brouwers M , Sutradhar R. (2020). Development and Validation of a Prognostic Survival Model With Patient-Reported Outcomes for Patients With Cancer.JAMA network open. 3(4): e201768.
Published,

39. Laurie SA , Banerji S , Blais N , Brule S , Cheema PK , Cheung P , Daaboul N , Hao D , Hirsh V , Juergens R , Laskin J , Leighl N , MacRae R , Nicholas G , Roberge D , Rothenstein J , Stewart DJ , Tsao MS. (2019). Canadian consensus: oligoprogressive, pseudoprogressive, and oligometastatic non-small-cell lung cancer.Current oncology (Toronto, Ont.). 26(1): e81-e93.
Published,

40. Goffin JR, Nicholas G, Mates M, Tu D, Chen E, Laurie SA, Juergens R, Robinson A, Goss G, Reaume M, Sun S, Christink K, Maize C, MacFarlan S, Sun X, Ritter H, Seymour L, Bradbury PA. (2019). Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens.Invest New Drugs. 37(3): 498-506.
Published,
Refereed?: Yes, Open Access?: No

41. Wang Y , Van Dam A , Slaven M , Ellis KJ , Goffin JR , Juergens RA , Ellis PM. (2019). Resource use in the last three months of life by lung cancer patients in southern Ontario.Current oncology (Toronto, Ont.). 26(4): 247-252.
Published,

42. Melosky B , Juergens R , McLeod D , Leighl N , Brade A , Card PB , Chu Q. (2019). Immune checkpoint-inhibitors and chemoradiation in stage III unresectable non-small cell lung cancer.Lung cancer (Amsterdam, Netherlands). 134: 259-267.
Published,

43. Melosky B , Chu Q , Juergens RA , Leighl N , Ionescu D , Tsao MS , McLeod D , Hirsh V. (2018). Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC.Cancer treatment reviews. 65: 65-77.
Published,

44. Juergens RA , Mariano C , Jolivet J , Finn N , Rothenstein J , Reaume MN , Faghih A , Labbé C , Owen S , Shepherd FA , Villeneuve J , Romeyer F , Pettersson F , Butts C. (2018). Real-world benefit of nivolumab in a Canadian non-small-cell lung cancer cohort.Current oncology (Toronto, Ont.). 25(6): 384-392.
Published,

45. Gettinger S , Hellmann MD , Chow LQM , Borghaei H , Antonia S , Brahmer JR , Goldman JW , Gerber DE , Juergens RA , Shepherd FA , Laurie SA , Young TC , Li X , Geese WJ , Rizvi N. (2018). Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 13(9): 1363-1372.
Published,

46. Melosky B, Blais N, Cheema P, Couture C, Juergens R, Kamel-Reid S, Tsao MS, Wheatley-Price P, Xu Z, Ionescu DN. (2018). Standardizing biomarker testing for Canadian patients with advanced lung cancer.Curr Oncol. 25(1): 73-82.
Published,

47. Gettinger S, Hellmann MD, Chow LQM, Borghaei H, Antonia S, Brahmer JR, Goldman JW, Gerber DE, Juergens RA, Shepherd FA, Laurie SA, Young TC, Li X, Geese WJ, Rizvi N. (2018). Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC.J Thorac Oncol. 2018(13): 9.
Published,

48. Melosky B , Cheema P , Agulnik J , Albadine R , Bebb DG , Blais N , Burkes R , Butts C , Card PB , Chan AMY , Hirsh V , Ionescu DN , Juergens R , Morzycki W , Poonja Z , Sangha R , Tehfe M , Tsao MS , Vincent M , Xu Z , Liu G. (2018). Canadian consensus: a new systemic treatment algorithm for advanced *EGFR*- mutated non-small-cell lung cancer. Current oncology (Toronto, Ont.). 25(5): 317-328.
Published,

49. Juergens RA, Bratman SV, Tsao MS, Laurie SA, Sara Kuruvilla M, Razak AR, Hansen AR. (2017). Biology and patterns of response to EGFR-inhibition in squamous cell cancers of the lung and head & neck.Cancer Treat Rev.54: 43-57.
Published,

50. Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, Ready N, Hiltermann TJN, Nair S, Juergens R, Peters S, Minenza E, Wrangle JM, Rodriguez-Abreu D, Borghaei H, Blumenschein GR Jr, Villaruz LC, Havel L, Krejci J, Corral Jaime J, Chang H, Geese WJ, Bhagavatheeswaran P, Chen AC, Socinski MA. (2017). First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.N Engl J Med.376(25): 2415-2426.
Published,
Refereed?: Yes, Open Access?: No

51. Nguyen NA, Isfahanian N, Pond G, Hanna W, Cutz JC, Wright J, Swaminath A, Shargall Y, Chow T, Wierzbicki M, Okawara G, Quan K, Finley C, Juergens R, Tsakiridis T. (2017). A Novel Neoadjuvant Therapy for Operable Locally Invasive Non-Small-Cell Lung Cancer. Phase I Study of Neoadjuvant Stereotactic Body Radiotherapy. LINNEARRE I (NCT02433574).Clin Lung Cancer. 18(4): 436-440.
Published,

52. Iafolla MAJ and Juergens RA. (2017). Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer.Front Oncol. 7(67): 1-14.
Published,

53. Matthew D. Hellmann, Naiyer A. Rizvi, Jonathan W. Goldman, Scott N. Gettinger, Hossein Borghaei, Julie R. Brahmer, Neal E. Ready, David E. Gerber, Laura Q. Chow, Rosalyn A. Juergens, Frances A. Shepherd, Scott A. Laurie, William J. Geese, Shruti Agrawal, Tina C. Young, Xuemei Li, Scott J. Antonia. (2017). Nivolumab plus Ipilimumab First-Line in Advanced Non–Small-Cell Lung Cancer.Lancet Oncol.18(1): 31-41.
Published,

54. Cabanero M, Sangha R, Sheffield BS, Sukhai M, Pakkal M, Kamel-Reid S, Karsan A, Ionescu D, Juergens RA, Butts C, Tsao MS. (2017). Management of EGFR-mutated non-small-cell lung cancer: practical implications from a clinical and pathology perspective.Curr Oncol. 24(2): 111-119.
Published,
Refereed?: Yes, Open Access?: No

55. Nadler M, Bainbridge D, Tomasone J, Cheifetz O, Juergens RA, Sussman J. (2017). Oncology care provider perspectives on exercise promotion in people with cancer: an examination of knowledge, practices, barriers, and facilitators.Support Care Cancer. 25(7): 2297-2304.
Published,

56. Melosky B, Agulnik J, Albadine R, Banerji S, Bebb DG, Bethune D, Blais N, Butts C, Cheema P, Cheung P, Cohen V, Deschenes J, Ionescu DN, Juergens R, Kamel-Reid S, Laurie SA, Liu G, Morzycki W, Tsao MS, Xu Z, Hirsh V. (2016). Canadian consensus:inhibition of ALK-positive tumours in advanced non-small-cell lung cancer. Curr Oncol. 23(3): 196-200.
Co-Author
Published,
Refereed?: Yes

57. Gettinger S, Rizvi NA, Chow LQ, Borghaei H, Brahmer J, Ready N, Gerber DE, Shepherd FA, Antonia S, Goldman JW, Juergens RA, Laurie SA, Nathan FE, Shen Y, Harbison CT, Hellmann MD. (2016). Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 34(25): 2980-2987.
Co-Author
Published,
Refereed?: Yes

58. Yiu KC, Juergens RA, Swaminath A. (2016). Multidisciplinary Influenceon Care of Lung Cancer Patients at the Time of Diagnosis: a Patient Survey. Clin Oncol (R Coll Radiol). 28(10): 667.
Published,

59. Leighl NB, Rizvi NA, de Lima LG Jr, Arpornwirat W, Rudin CM, Chiappori AA, Ahn MJ, Chow LQ, Bazhenova L, Dechaphunkul A, Sunpaweravong P, Eaton K, Chen J, Medley S, Poondru S, Singh M, Steinberg J, Juergens RA, Gadgeel SM. (2016). Phase 2 Study of Erlotinib in Combination With Linsitinib (OSI-906) or Placebo in Chemotherapy-Naive Patients With Non-Small-Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations.Clin Lung Cancer. 8(16): S1525, 30187-5.
Co-Author
Published,
Refereed?: Yes
Number of Contributors: 19

60. Rizvi NA, Hellmann MD, Brahmer JR, Juergens RA, Borghaei H, Gettinger S, Chow LQ, Gerber DE, Laurie SA, Goldman JW, Shepherd FA, Chen AC, Shen Y, Nathan FE, Harbison CT, Antonia. (2016). Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of AdvancedNon-Small-Cell Lung Cancer. J Clin Oncol. 34(25): 2969-2979.
Published,
Refereed?: Yes

61. Macaulay VM, Middleton MR, Eckhardt SG, Rudin CM, Juergens RA, Gedrich R, Gogov S, McCarthy S, Poondru S, Stephens AW, Gadgeel SM. (2016). Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced SolidTumors. Clin Cancer Res. 22(12): 2897-2907.
Published,

62. Melosky B, Chu Q, Juergens R, Leighl N, McLeod D, Hirsh V. (2016). Pointed Progress inSecond-Line Advanced Non-Small-Cell Lung Cancer: The Rapidly Evolving Field of Checkpoint Inhibition. J Clin Oncol. 34(14): 1676-88.
Co-Author
Published,
Refereed?: Yes, Open Access?: Yes

63. 7. Juergens RA, Zukotynski KA, Singnurkar A, Snider DP, Valliant JF, Gulenchyn KY. (2016). Imaging Biomarkers in Immunotherapy. Biomark Cancer. 8(Suppl 2): 1-13.
First Listed Author
Published,
Refereed?: Yes, Open Access?: No

64. Juergens RA , Rudin CM. (2013). Aberrant epigenetic regulation.American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting. 2013,

65. Halmos B , Jia Y , Bokar JA , Fu P , Adelstein DJ , Juergens R , Rodal MB , Dowlati A. (2013). A Phase I Study of the combination of oxaliplatin/docetaxel and vandetanib for the treatment of advanced gastroesophageal cancer.Investigational new drugs. ,

66. Tsao A , Hui EP , Juergens R , Marur S , Huat TE , Cher GB , Hong RL , Hong WK , Chan AT. (2013). Phase II study of TAS-106 in patients with platinum-failure recurrent or metastatic head and neck cancer and nasopharyngeal cancer.Cancer medicine. 2(3),

67. Rudin CM , Brahmer JR , Juergens RA , Hann CL , Ettinger DS , Sebree R , Smith R , Aftab BT , Huang P , Liu JO. (2013). Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 8(5),

68. Wrangle J, Wang W, Koch A, Easwaran H, Mohammad HP, Vendetti F, Vancriekinge W, Demeyer T, Du Z, Parsana P, Rodgers K, Yen RW, Zahnow CA, Taube JM, Brahmer JR, Tykodi SS, Easton K, Carvajal RD, Jones PA, Laird PW, Weisenberger DJ, Tsai S, Juergens RA, Topalian SL, Rudin CM, Brock MV, Pardoll D, Baylin SB. (2013). Alterations of immune response of Non-Small Cell Lung Cancer with Azacytidine.Oncotarget. 4(11),

69. Levine MN , Juergens R. (2012). Method to our madness or madness in our methods? Pitfalls in trial methodology.Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 30(17),

70. Juergens RA , Wrangle J , Vendetti FP , Murphy SC , Zhao M , Coleman B , Sebree R , Rodgers K , Hooker CM , Franco N , Lee B , Tsai S , Delgado IE , Rudek MA , Belinsky SA , Herman JG , Baylin SB , Brock MV , Rudin CM. (2011). Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer.Cancer discovery. 1(7),

71. Rudin CM , Mauer A , Smakal M , Juergens R , Spelda S , Wertheim M , Coates A , McKeegan E , Ansell P , Zhou X , Qian J , Pradhan R , Dowell B , Krivoshik A , Gordon G. (2011). Phase I/II study of pemetrexed with or without ABT-751 in advanced or metastatic non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 29(8),

72. Paik PK , Rudin CM , Pietanza MC , Brown A , Rizvi NA , Takebe N , Travis W , James L , Ginsberg MS , Juergens R , Markus S , Tyson L , Subzwari S , Kris MG , Krug LM. (2011). A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer.Lung cancer (Amsterdam, Netherlands). 74(3),

73. Paik PK , Rudin CM , Brown A , Rizvi NA , Takebe N , Travis W , James L , Ginsberg MS , Juergens R , Markus S , Tyson L , Subzwari S , Kris MG , Krug LM. (2010). A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies.Cancer chemotherapy and pharmacology. 66(6), , Open Access?: Yes

74. Burns TF , Juergens RA. (2010). Bevacizumab in advanced lung cancer: in search of the right drug for the right patient.Oncology (Williston Park, N.Y.). 24(13),

Book Chapters

1. Juergens, RA. (2011). Take Action: Comprehensive Treatment Options in Lung Cancer. J. Klamerus MD, J. Brahmer MD, and D. Ettinger MD. The Johns Hopkins Guide to Lung Cancer. : 23-62.
   First Listed Author
   Published, Jones and Bartlett Learning, United States of America
   Number of Contributors: 1

Thesis/Dissertation

1. Targeting Epigenetic Changes in Non-Small Cell Lung Cancer. (2012). Johns Hopkins University. Doctorate. Supervisor: Charles Rudin, MD PhD

Reports

1. Co-Author. Normand Blais, Quincy Chu, Peter Ellis, Meredith Giuliani, Diana Ionescu, Rosalyn Juergens, Stephen Lam, Janessa Laskin, Natasha Leighl, Donna Maziak, Jefrey Rothenstein, Yee Ung, Zhaolin Xu. (2015). 2015 Faces of Lung Cancer Report. 20. Lung Cancer Canada.
   Number of Contributors: 24
2. Co-Author. Paul Wheatley-Price, Normand Blais, Quincy Chu, Meredith Giuliani, Cheryl Ho, Diana Ionescu, Rosalyn Juergens, Stephen Lam, Natasha Leighl, Donna Maziak, Jeffrey Rothenstein, Yee Ung, Zhaolin Xu. (2014). 2014 Faces of Lung Cancer Report - Fighting Disease, Fighting Disparity. 43. Lung Cancer Canada.
   Number of Contributors: 12

Online Resources

1. First Listed Author. R.A. Juergens. Dr. Rosalyn Juergens: Recommending a Repeat Biopsy with Acquired Resistance to a Targeted Therapy. (2013).
   Editors: J. West
2. First Listed Author. Dr. Rosalyn Juergens: How Do You Discuss the Pros and Cons of Molecular Testing, with Potential Delays and Need for Rebiopsy?. (2013).
   Editors: Jack West, MD
3. First Listed Author. R.A Juergens. Dr. Rosalyn Juergens on the Utility of Molecular Marker Results in the Adjuvant Setting for Early Stage Non-Small Cell Lung Cancer. (2013).
   Editors: J. West
4. First Listed Author. R.A. Juergens. Dr. Rosalyn Juergens: What Novel Therapies Are You Most Optimistic About as Potential Lung Cancer Treatments in the Next Few Years?. (2013).
   Editors: J. West
5. First Listed Author. R.A. Juergens. Dr. Rosalyn Juergens on “I Just Found Out I Have an EGFR Mutation, and I’m in the Middle of Chemo. What Now?”. (2013).
   Editors: J. West
6. First Listed Author. R.A. Juergens. Dr. Rosalyn Juergens: Will New Forms of Mutation Testing Become Available Beyond the Major Research Centers?. (2013).
   Editors: J. West

7. R. A. Juergens. Dr. Rosalyn Juergens on “My Approach to Maintenance Therapy for Advanced NSCLC”. (2013).
Editors: J. West

8. First Listed Author. R.A Juergens. Dr. Rosalyn Juergens on Managing Acquired Resistance to Targeted Therapies for Advanced NSCLC. (2013).
Editors: J. West

9. Co-Author. D. Ettinger, J. West, R.A. Juergens. Today’s Patient in Non–Small-Cell Lung Cancer: Does Histology Make A Difference? An Interactive E-Platform Featuring Patient Simulations. (2010).
Number of Contributors: 3
Editors: D. Ettinger
Description / Contribution Value: An Interactive E-Platform Featuring Patient Simulations

10. Last Author. Daniel Laheru, MD; Anthony Boutros El-Khoueiry, MD; Nilofer Azad, MD; Rosalyn Juergens, MD. Expert Perspectives: GI Cancers Update, 2010. (2010).
Number of Contributors: 4
Editors: D. Laheru

Conference Publications

1. Antonia SJ, Gettinger SN, Goldman J, Brahmer J, Borghaei H, Chow LQ, Ready NE, Gerber DE, Juergens R, Shepherd F, Laurie SA, Young T, Geese WJ, Agrawal S, Li X, Hellmann MD.CheckMate 012: Safety and Efficacy of First-Line Nivolumab and Ipilimumab in Advanced NSCLC:. IASLC 2016 Chicago Multidisciplinary Symposium in Thoracic Oncology., Chicago, United States of America,
Poster
Refereed?: Yes, Invited?: No

2. Dimas Yusuf, Jenny J. Ko, Hyokeun Cho, Corey Sheremeto, Ying Wang, Rosalyn A. Juergens, Peter Michael Ellis, Alkarim Billawala, Amin Kay, Swati Kulkarni, Tarek A. Elfiki, Rasna Gupta, Krista Naccarato, Alex Pennetti, Devalben Patel, Elliot Charles Smith, Ryan Walton, Manjusha Hurry, Geoffrey Liu, Winson Y. Cheung.Real-world outcomes for metastatic non-small cell lung cancer patientstreated with checkpoint inhibitor immunotherapy in Canada.American Society of Clinical Oncology / Society for Immunotherapy in Cancer Meeting., Orlando, United States of America,
Conference Date: 2020/2
Poster
Refereed?: Yes, Invited?: No

3. Jason Agulnik, Jennifer H. Law, Rosalyn Juergens, Janessa Laskin, Scott Laurie, Desiree Hao, Doreen Ezeife, Lisa Le, Lesli A. Kiedrowski, Richard B. Lanman, Natasha Leighl.Defining VALUE: Routine liquid biopsy in NSCLC diagnosis - a Canadian trial in progress.AACR Special Conference on Advances in Liquid Biopsies., Miami, United States of America,
Conference Date: 2020/1
Poster
Refereed?: Yes, Invited?: No

4. Michael Bonert, Asghar Naqvi, Christian Finley, Rosalyn Juergens, Phillip Williams, Pierre Major, Anil Kapoor.Communication with pathology evaluated via the pathology requisition using 396,033 pathology reports.European Congress of Pathology., Nice, France,
Conference Date: 2019/9
Abstract
Refereed?: Yes, Invited?: No

5. R. Wong, D. Laidley, S. D. Myrehaug, J. Brierley, R. Juergens, I. W. T. Yeung, S. Breen, B. Driscoll,A. Shessel, T. Farncombe, K. Zukotynski, R. Stodilka, C. B. Caldwell, Z. Liu, J. Valliant, J. McCann, U. Metser, R. Mohan, J. M. Beauregard, and D. A. Jaffray.Quantifying Renal And Tumor Doses With Individualized Dosimetry In 177Lu DOTATATE Therapy – What Difference Does It Make?. American Society for Radiation Oncology., Chicago, United States of America,
Conference Date: 2019/9
Poster
Refereed?: Yes, Invited?: No

6. Rosalyn Anne Juergens, Peter M Ellis, Dongsheng Tu, Desiree Hao, Scott A Laurie, Mihaela Mates, Glenwood D. Goss, John Goffin, Penelope A Bradbury, Mustapha Tehfe, Christian Kollmansberger, Pamela Brown-Walker, Martin Smoragiewicz, Ming Sound Tsao, Lesley Seymour.Platinum Doublet + Durvalumab +/- Tremelimumab in Patients with Advanced NSCLC: A CCTG Phase IB Study - IND.226.World Congress on Lung Cancer, Barcelona, Spain,
Conference Date: 2019/9
Abstract
Refereed?: Yes, Invited?: No

7. Arani Sathiyapalan, Ying Wang, , Martin Butcher, Asghar Naqvi, Jean-Claude Cutz, Rosalyn Anne Juergens.Updated Analysis of Outcomes by Histology vs Cytology PD-L1 22C3 Antibody Testing in Advanced Non-Small Cell Lung Cancer.World Congress on Lung Cancer, Barcelona, Spain,
Conference Date: 2019/9
Poster
Refereed?: Yes, Invited?: No

8. Michael Bonert, Jean-Claude Cutz, Christian Finley, Ihab El-Shinnawy, Samih Salama, Gabriella Gohla, Salem Alowami, Dusan Lukic, Farnoosh Tayyari, Rosalyn Juergens, Asghar Naqvi.Visceral Pleural Invasion by Tumour Size, Cancer Type and Pathologist in 1,560 Resections.European Congress of Pathology, Nice, France,
Conference Date: 2019/9
Abstract
Refereed?: Yes, Invited?: No

9. D Hao; P M Ellis; S A Laurie; R A Juergens; M Mates; P A Bradbury; M Tsao; M Tehfe; C K Kollmannsberger; J R Goffin; P Wheatley-Price; J Hilton; A G Robinson; P Brown-Walker; D Tu; M Smoragiewicz; L K Seymour.Pharmacokinetic (PK) and updated survival data from the Canadian cancer trials group IND.226 study of durvalumab ± tremelimumab in combination with platinum-doublet chemotherapy.European Society of Medical Oncology Annual Meeting, Barcelona, Spain,
Conference Date: 2019/9
Poster
Refereed?: Yes, Invited?: No

10. Rosalyn A. Juergens, Katherine A. Zukotynski, Daniel Juneau, Lily Krnezich, Ryan Simms, John Forbes, Eric S. Burak, John Valliant, Lauren Stafford, Thomas Armor, Istvan Molnar, Fred Saad.A phase I study of [225Ac]-FPI-1434 radioimmunotherapy in patients with IGF-1R expressing solid tumors.American Society of Clinical Oncology Annual Meeting, Chicago, United States of America,
Conference Date: 2019/6
Poster
Refereed?: Yes, Invited?: No

11. Rosalyn A. Juergens, Quincy S. Chu, Daniel John Renouf, Scott Andrew Laurie, Daniela Purcea, Elaine McWhirter, Diane Arndt, Karen A. Gelmon, John Hilton, Bruno Gavillet, Peter Michael Ellis, Michael B. Sawyer, Christian K. Kollmannsberger, Natalie Andrews Wright, Elisabeth Rouits, Frank Brichory, Gregoire Vuagniaux, Sergio A. Szyldergemajn, Glenwood Goss.A dose-finding study of the SMAC mimetic Debio 1143 when given in combination with avelumab to patients with advanced solid malignancies.American Society of Clinical Oncology Annual Meeting, Chicago, United States of America,
Conference Date: 2019/6
Poster
Refereed?: Yes, Invited?: No

12. Martin Früh, Osama E. Rahma, Russell K. Pachynski, Julien Mazières, Jerome Goldschmidt, Jr, Thanh G. N. Ton, Shivani K. Mhatre, Ching-Yi Chuo, Jorge Martinalbo, Jessica Davies, Rosalyn Juergens.Characteristics of Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Receiving Atezolizumab Monotherapy in US Clinical Practice.European Lung Cancer Conference., Geneva, Switzerland,
Conference Date: 2019/4
Poster
Refereed?: Yes, Invited?: No

13. S Colomer-Lahiguera; D Bryant-Lukosius; S Rietkoetter; L Martelli; K Ribi; A Orcurto; R Juergens; M Eicher.The use of patient reported outcome (PRO) instruments in immune checkpoint inhibitor (ICI) therapy for cancer: A systematic review.European Society of Medical Oncology Annual Meeting., Munich, Germany,
Conference Date: 2018/10
Poster
Refereed?: Yes, Invited?: No

14. Doreen Anuli Ezeife | Author(s): Jason S Agulnik, Rosalyn Juergens, Janessa Laskin, Scott A. Laurie, Lisa Le, Desiree Hao, Gwyn Bebb, Jennifer H Law, Stan Skrzypczak, Daniela Juri, Richard B Lanman, Natasha B Leighl.Achieving Value in Cancer Diagnostics: Blood Versus Tissue Molecular Profiling - A Prospective Canadian Study (VALUE).World Congress on Lung Cancer, Toronto, Canada,
Conference Date: 2018/9
Poster
Refereed?: Yes, Invited?: No

15. Parneet Kaur Cheema, Geoffrey Liu, Ronald Burkes, Scott Owen, Joanne Yu, Desiree Hao, Jeffrey Rothenstein, Simon Martel, Mussawar Iqbal, Rosalyn Juergens, Wendy Lam, Janessa Laskin.Real-World Study of Osimertinib in EGFR T790M-Mutated Non-Small Cell Lung Cancer (NSCLC): ASTRIS Canadian Cohort Analysis.World Congress on Lung Cancer., Toronto, Canada,
Conference Date: 2018/9
Poster
Refereed?: Yes, Invited?: No

16. Scott J Antonia, Scott N. Gettinger, Hossein Borghaei, Jonathan W. Goldman, Julie R. Brahmer, Neal E. Ready, David E Gerber, Laura Q Chow, Rosalyn Juergens, Scott A. Laurie, Frances A Shepherd, Xuemei Li, Ang Li, William J. Geese, Matthew D. Hellmann.Long-Term Outcomes with First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 3-Year Follow-Up from CheckMate 012.World Congress on Lung Cancer., Toronto, Canada,
Conference Date: 2018/9
Abstract
Refereed?: Yes, Invited?: No

17. Ying Wang, Martin Butcher, Asghar Naqvi, Jean-Claude Cutz, Rosalyn Juergens.Clinical Outcomes of Histology Versus Cytology PD-L1 22C3 Antibody Testing in Advanced Non-Small Cell Lung Cancer.World Congress on Lung Cancer., Toronto, Canada,
Conference Date: 2018/9
Poster
Refereed?: Yes, Invited?: No

18. 17. Rosalyn Juergens | Author(s): Martin Butcher, Asghar Naqvi, Jean-Claude Cutz, Michael Bonert.Optimization of PD-L1 Testing Specimen Flow in the Greater Hamilton, Ontario Region.World Congress on Lung Cancer, Toronto, Canada,
Conference Date: 2018/9
Poster
Refereed?: Yes, Invited?: No

19. C. Fahim, J. Agzarian, W. Hanna, R. Juergens, Y. Shargall, M. Simunovic.High physician confidence does not predict rate or type of treatment change for cases discussed at a thoracic multidisciplinary cancer conference: A case series in a tertiary cancer center.European Lung Cancer Conference., Geneva, Switzerland,
Conference Date: 2018/4
Poster
Refereed?: Yes, Invited?: No

20. R. Juergens, Q. Chu, J. Rothenstein, F. De Angelis, S. Banerji, K. Marquis, D. Sauciuc, P. Begin, N. Finn, V. Hirsh, A. Faghih, J. Yun, A. Li, A. Acevedo, L. Musallam, P. Cheema.CheckMate 169: Safety/Efficacy of Nivolumab in Canadian Pretreated Advanced NSCLC (including Elderly and PS 2) Patients.World Congress on Lung Cancer, Yokohama, Japan,
Conference Date: 2017/11
Poster
Refereed?: Yes, Invited?: No

21. R. Juergens, D. Hao, S. Laurie, P. Ellis, M. Mates, P. Bradbury, M. Tehfe, C. Kollmannsberger, A. Arnold, J. Goffin, P. Wheatley-Price, J. Hilton, A. Robinson, D. Tu, P. Brown-Walker, L. Seymour.Durvalumab ± Tremelimumab with Platinum-Doublets in Non-Small Cell Lung Cancer: Canadian Cancer Trials Group Study IND.226.World Congress on Lung Cancer, Yokohama, Japan,
Conference Date: 2017/11
Abstract
Refereed?: Yes, Invited?: No

22. R. Juergens, M. Hellmann, J. Brahmer, H. Borghaei, S. Gettinger, L. Chow, D. Gerber, S. Laurie, J. Goldman, F. Shepherd, W. Geese, T. Young, X. Li, S. Antonia.First-Line Nivolumab plus Platinum-Based Doublet Chemotherapy for Advanced NSCLC: CheckMate 012 3-Year Update.World Congress on Lung Cancer, Yokohama, Japan,
Conference Date: 2017/11
Abstract
Refereed?: Yes, Invited?: No

23. Q.S-C. Chu; C. van Herpen; N.B. Leighl; B. Markman; S. Clarke; R.A. Juergens; P. Basciano; D. Lathers; S. Tannenbaum-Dvir; K. Urbanska; G. Kollia; C. Darby; D. Williams; G. Kolaitis; N. Ready.Initial results of BMS-986012, a first-in-class fucosyl-GM1 mAb, in combination with nivolumab, in pts with relapsed/ refractory (rel/ref) small-cell lung cancer (SCLC).European Society of Medical Oncology Annual Meeting., Madrid, Spain,
Conference Date: 2017/9
Poster
Refereed?: Yes, Invited?: No

24. Rosalyn Juergens, Desiree Hao, Scott Laurie, Mihaela Mates, Mustapha Tehfe, Penelope Bradbury, Christian Kollmannsberger, Peter Ellis, John Hilton, Pamela Brown-Walker, Lesley Seymour.Cisplatin/ Pemetrexed + Durvalumab +/- Tremelimumab in Pts with Advanced Non-Squamous NSCLC: A CCTG Phase IB Study - IND.226.World Congress on Lung Cancer, Vienna, Austria,
Conference Date: 2016/12
Abstract
Refereed?: Yes, Invited?: No

25. Scott Gettinger, Naiyer Rizvi, Laura Chow, Hossein Borghaei, Julie Brahmer, Frances Shepherd, Neal Ready, David Gerber, Scott Antonia, Jonathan W. Goldman, Rosalyn Juergens, William Geese, Tina Young, Xuemei Li, Matthew Hellmann..First-Line Nivolumab Monotherapy and Nivolumab plus Ipilimumab in Patients with Advanced NSCLC: Long-Term Outcomes from CheckMate 012.World Congress on Lung Cancer, Vienna, Austria,
Conference Date: 2016/12
Poster
Refereed?: Yes, Invited?: No

26. N.A. Rizvi, S.N. Gettinger, J.W. Goldman, M.D. Hellmann, L.Q. Chow, R. Juergens, H. Borghaei, J.R. Brahmer, Y. Shen, C. Harbison, F. Nathan, N. Ready, S.J. Antonia.Safety and Efficacy of First-Line Nivolumab (NIVO; Anti-Programmed Death-1 [PD-1]) and Ipilimumab in Non-Small Cell Lung Cancer (NSCLC).World Congress on Lung Cancer, Vienna, Austria,
Conference Date: 2016/12
Poster
Refereed?: Yes, Invited?: No

27. D. Hao, R. Juergens, S. A. Laurie, M. Mates, M. Tehfe, P. Bradbury, C. Kollmannsberger, P. Ellis, J. Hilton, P. Brown-Walker, L. Seymour.A Canadian Cancer Trials Group phase IB study of durvalumab with or without tremelimumab + standard platinum-doublet chemotherapy in patients with advanced, incurable solid malignancies (IND.226).EORTC-NCI-AACR Symposium, Munich, Germany,
Conference Date: 2016/11
Poster
Refereed?: Yes, Invited?: No

28. M. Socinski, B. Creelan, L. Horn, M. Reck, L. Paz-Ares, M. Steins, E. Felip, M. van den Heuvel, T.E. Ciuleanu, F. Badin, N. Ready, J.N. Hiltermann, S. Nair, R. Juergens, S. Peters, E. Minenza, W.J. Geese, P. Bhagavatheeswaran, A. Chen, D.P. Carbone.CheckMate 026: A Phase 3 trial of nivolumab vs investigator's choice (IC) of platinum-based doublet chemotherapy (PT-DC) as first-line therapy for stage IV/recurrent programmed death ligand 1 (PD-L1)-positive NSCLC.European Society of Medical Oncology Annual Meeting, Copenhagen, Denmark,
Conference Date: 2016/10
Poster
Refereed?: Yes, Invited?: No

29. Matthew David Hellmann, Scott N. Gettinger, Jonathan Wade Goldman, Julie R. Brahmer, Hossein Borghaei, Laura Q. Chow, Neal Ready, David E. Gerber, Rosalyn A. Juergens, Frances A. Shepherd, Scott Andrew Laurie, Ye Zhou, William J. Geese, Shruti Agrawal, Xuemei Li, and Scott Joseph Antonia. (2016). CheckMate 012: Safety andefficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) inadvanced (adv) NSCLC. ASCO, Chicago, United States of America,
Conference Date: 2016/5
Abstract
Co-Author
Published

30. Naiyer Rizvi, Scott N. Gettinger, Jonathan Goldman, Matthew D. Hellmann, Laura Q. Chow, Rosalyn Juergens, Hossein Borghaei, Julie Brahmer, Yun Shen, Christopher Harbison, Faith Nathan, Neal E. Ready, Scott Antonia. (2015). Safety and efficacy of first?line nivolumab (NIVO; anti?programmed death-1 [PD?1]) and ipilimumab (IPI) in non-small cell lung cancer (NSCLC). ECCO, ,
Abstract
Co-Author
Published

31. Rosalyn Juergens, Som Mukherjee, Sebastien Hotte, Hal Hirte, Elaine McWhirter, Anita Bane, Mark Levine, Karen Gulenchyn, John Valliant. (2015). Imaging the Insulin-LikeGrowth Factor Receptor 1 (IGF-1R):A First in Human Phase I Imaging ClinicalTrial. Canadian Cancer Research Conference, Montreal, Canada,
Conference Date: 2015/9
Abstract
First Listed Author
Published

32. Scott N. Gettinger, Frances A. Shepherd, Scott Joseph Antonia, Julie R. Brahmer, Laura Quan Man Chow, Rosalyn A. Juergens, Hossein Borghaei, Yun Shen, Christopher Harbison, Suresh Alaparthy, Allen C. Chen, Naiyer A. Rizvi. (2015). First-line monotherapy with nivolumab (NIVO; anti-programmed death-1 [PD-1]) in advanced non-small cell lung cancer (NSCLC): safety, efficacy and correlation of outcomes with PD-1 ligand (PD-L1) expression.ASCO, Chicago, United States of America,
Conference Date: 2015/5
Abstract
Co-Author
Published

33. S.N. Gettinger, M.D. Hellmann, F.A. Shepherd, S.J. Antonia, J. Brahmer, L.Q. Chow, J. Goldman, R. Juergens, H. Borghaei, N.E. Ready, D.E. Gerber, F. Nathan, Y. Shen, C.T. Harbison, N. Rizvi. (2014). First-linemonotherapy with nivolumab (NIVO) in advanced non-small cell lung cancer(NSCLC). CMTSO, ,
Abstract
Co-Author
Published

34. S. Gettinger, N. Rizvi, L. Q. Chow, H. Borghaei, J. R. Brahmer, R. Juergens, F. A. Shepherd, S. A. Laurie, D. E. Gerber, J. W. Goldman, Y. Shen, C. Harbison, A. Chen, S. J. Antonia. (2014). 1054PD - Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) or erlotinib (ERL) in advanced non-small cell lung cancer (NSCLC). ESMO 2014 Congress, ,
Conference Date: 2014/9
Abstract
Co-Author
Published
Refereed?: Yes, Invited?: No

35. Scott N. Gettinger, Frances A. Shepherd, Scott Joseph Antonia, Julie R. Brahmer, Laura Quan Man Chow, Rosalyn A. Juergens, Hossein Borghaei, Yun Shen, Christopher Harbison, Suresh Alaparthy, Allen C. Chen, and Naiyer A. Rizvi. (2014). First-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: Safety, efficacy, and correlation of outcomes with PD-L1 status.Americal Society of Clinical Oncology Annual Meeting 2014, ,
Conference Date: 2014/6
Abstract
Co-Author
Published
Refereed?: Yes, Invited?: No

36. Scott Joseph Antonia, Scott N. Gettinger, Laura Quan Man Chow, Rosalyn A. Juergens, Hossein Borghaei, Yun Shen, Christopher Harbison, Allen C. Chen, Neal Ready, and Naiyer A. Rizvi. (2014). Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results.American Society of Clinical Oncology Annual Meeting 2014, ,
Conference Date: 2014/6
Abstract
Co-Author
Published, Invited?: No

37. Scott Joseph Antonia, Julie R. Brahmer, Scott N. Gettinger, Laura Quan Man Chow, Rosalyn A. Juergens, Frances A. Shepherd, Scott Andrew Laurie, David E. Gerber, Jonathan Wade Goldman, Yun Shen, Christopher Harbison, Suresh Alaparthy, Allen C. Chen, Hossein Borghaei, and Naiyer A. Rizvi. (2014). Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC).American Society of Clinical Oncology Annual Meeting 2014, ,
Conference Date: 2014/6
Abstract
Co-Author
Published
Refereed?: Yes, Invited?: No

38. Naiyer A. Rizvi, Scott J. Antonia, Laura Q. Chow, Julie R. Brahmer, Rosalyn A. Juergens, Hossein Borghaei, Frances A. Shepherd, Scott Andrew Laurie, David E. Gerber, Jonathan Wade Goldman, Yun Shen, C. (2013). A phase I study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus platinum-based doublet chemotherapy (PT-doublet) in chemotherapy-naive non-small cell lung cancer (NSCLC) patients (pts).ASCO, Chicago, ,
Conference Date: 2013/5
Poster
Co-Author
Accepted

39. Mark Socinski, Rosalyn Juergens, Fiona Blackhall, Rafael Rosell, Iman El-Hariry, Vojo Vukovic, Florentina Teofilovici, Isra Isa, Glenwood Goss. (2012). The CHIARA Trial (NCT01562015): A single arm, phase 2 study of ganetespib in patients with advanced non-small-cell lung cancer with anaplastic lymphoma kinase gene rearrangement (ALK-positive NSCLC).ESMO, Vienna, Austria,
Conference Date: 2012/9
Abstract
Co-Author
Published

40. J.M. Wrangle, H.P. Mohammad, A. Abukhdeir, R.A. Juergens, K. Harbom, K. Rodgers, J.Shin, C.A. Zahnow, S.Baylin, J.Herman, C.M. Rudin, M.V. Brock. (2012). Predicting sensitivity to azacytidine in non-small cell cancer lines by absence of activating mutations.ASCO, Chicago, IL, ,
Conference Date: 2012/5
Abstract
Co-Author
Published, Invited?: Yes

41. J.M. Wrangle, R.A. Juergens, F. Vendetti, , B. Coleman, R.S. Sebree, M.A. Rudek, S.Belinsky, J. Herman, S. Baylin, C.M. Rudin. M.V. Brock. (2011). Biomarker Development for a Phase II Study of Combination Epigenetic Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC).World Conference on Lung Cancer, Amsterdam, Netherlands, ,
Conference Date: 2011/7
Poster
Co-Author
Published, Invited?: Yes

42. B. Halmos, J. Bokar, P. Fu, D. Adelstein, R. Juergens, M.B. Rodal, A. Dowlati. (2011). A Phase I Study of the combination of oxaliplatin / docetaxel and vandetanib for the treatment of advanced gastroesophageal (GE) cancer.ASCO, Chicago, IL, ,
Conference Date: 2011/6
Poster
Co-Author
Published, Invited?: Yes

43. V.M. Macaulay, M.R. Middleton, S.G. Eckhardt, R. Juergens, C. M. Rudin, A. Manukyants, S. Gogov, S. Poondru, R. Gedrich and S. Gadgeel. (2011). Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors.ASCO, Chicago, IL, ,
Conference Date: 2011/6
Poster
Co-Author
Published, Invited?: Yes

44. R.A. Juergens, F. Vendetti, J. Wrangle, B. Coleman, R.S. Sebree, M.A. Rudek, S.Belinsky, M. Brock, J. Herman, S. Baylin, C.M. Rudin. (2011). A phase II study of combination epigenetic therapy in advanced non-small cell lung cancer (NSCLC).Amercian Association for Cancer Research Annual Meeting, Orlando, FL, ,
Conference Date: 2011/4
Abstract
First Listed Author
Published, Invited?: Yes

45. R.A. Juergens, F. Vendetti, J. Wrangle, B. Coleman, R.S. Sebree, M.A. Rudek, S.Belinsky, M. Brock, J. Herman, S. Baylin, C.M. Rudin. (2011). Analysis of a Phase II trial of 5-azacitidine(5AC) and entinostat (SNDX-275) in relapsed advanced lung cancer.5th Biennial Workshop on the Clinical Translation of Epigenetics in Cancer Therapy., San Diego, CA, ,
Conference Date: 2011/1
Poster
First Listed Author
Published, Invited?: Yes

46. V. M. Macaulay, M. R. Middleton, S. G. Eckhardt, R. A. Juergens, A. W. Stephens, S. Poondru, S. P. McCarthy, and S. M. Gadgeel. (2010). Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors.ASCO Meeting Abstracts. ASCO, (3016),
Conference Date: 2010/6
Abstract
Co-Author
Published
Refereed?: Yes, Invited?: Yes

Protected when completed

Date Submitted: 2025-01-17 09:56:19
Confirmation Number: 1896114
Template: CIHR Biosketch

Dr. Boyang Zhang

Correspondence language: English
Sex: Male
Date of Birth: 6/02
Canadian Residency Status: Canadian Citizen
Country of Citizenship: Canada

Contact Information

The primary information is denoted by (*)

Address

Primary Affiliation (*)

A416, John Hodgins Engineering
1280 Main Street West
Hamilton Ontario L8S 4L7
Canada

Telephone

Mobile (*)	416-8331865

Email

Personal	bzhang7@gmail.com
Work (*)	zhangb97@mcmaster.ca

Website

Personal	www.bzhanglab.com

CIHR IRSC
Canadian Institutes of Health Research | Instituts de recherche en santé du Canada

Canadian Common CV | commun canadien

Protected when completed

Dr. Boyang Zhang

Degrees

2017/4 - 2018/6	Post-doctorate, Banting Fellow, University of Toronto Degree Status: Completed
2010/9 - 2016/4	Doctorate, Chemical Engineering and Applied Chemistry, University of Toronto Degree Status: Completed
2006/8 - 2010/5	Bachelor's, Chemical and Biomolecular Engineering, Georgia Institute of Technology Degree Status: Completed

Recognitions

2022/11	2022 McMaster Innovator of the Year Award Nominee McMaster University
2022/4 - 2027/4	Ontario Early Career Researcher Award Government of Ontario
2021/11	Lab on a Chip Outstanding Reviewer of 2021 Royal Society of Chemistry, Lab on a Chip Journal
2020/8	Special Young Scholar, Global Chinese Chemical Engineering The Global Chinese Chemical Engineering Society
2019/3	Biofabrication Outstanding Reviewer of 2018 Biofabrication journal

Employment

2023/7	Associate Professor Chemical Engineering, Engineering, McMaster University
2021/4	Co-founder of OrganoBiotech, Inc. OrganoBiotech
2021/7 - 2027/6	Department Associate Chair (Graduate) Chemical Engineering, Engineering, McMaster University
2017/1 - 2027/1	Consultant for Yole Development Yole Development
2023/11 - 2024/1	Consultant for VALO Health VALO Health
2018/7 - 2023/7	Assistant Professor Department of Chemical Engineering and Applied Chemistry, Faculty of Engineering, McMaster University

2016/4 - 2018/7	Banting Post-doctoral Fellow Institute of Biomaterials and Biomedical Engineering, Faculty of Engineering, University of Toronto
2014/7 - 2018/7	Co-founder of TARA Biosystems, Inc. TARA Biosystems
2010/7 - 2016/4	Graduate researcher, Laboratory of Functional Tissue Engineering Department of Chemical Engineering and Applied Chemistry, Faculty of Engineering, University of Toronto
2012/9 - 2014/8	Member of the Process Technology Committee (PTC) Department of Mechanical Engineering, Faculty of Engineering, University of Toronto
2007/8 - 2010/5	Undergraduate researcher, Lu Fluidics Groups Department of Chemical and Biomolecular Engineering, Faculty of Engineering, Georgia Institute of Technology

Affiliations

The primary affiliation is denoted by (*)

(*) 2018/7	Assistant Professor, Chemical Engineering, McMaster University

Research Funding History

Awarded [n=22]

2025/1 - 2030/1
Co-investigator

Uncovering the role of physiologically relevant biliary signaling in engineering 3D bile duct tubes with human pluripotent stem cell-derived cholangiocytes

Funding Sources:
Canadian Institutes of Health Research (CIHR)
Project Grant
Total Funding - 1,280,000
Funding Competitive?: Yes

Principal Investigator : Shinichiro Ogawa

2022/4 - 2027/4
Principal Applicant

Platform Technology for High-throughput Drug Screening/Operating Grant

Funding Sources:
Early Researcher Award/ Ontario Research Fund
Early Researcher Award
Total Funding - 150,000
Funding Competitive?: Yes

2021/8 - 2026/8
Principal Applicant

Development of clinical trial on-a-plate for the preparation of future pandemics

Funding Sources:
National Sanitarium Association
The NSA Scholars Program
Total Funding - 994,000
Funding Competitive?: Yes

2024/4 - 2026/4
Co-investigator

Investigating oxidative stress and cellular function as biomarkers of preeclampsia subtypes using placenta-on- a-chip

Funding Sources:
New Frontiers in Research Fund - Exploration
New Frontiers in Research Fund - Exploration
Total Funding - 250,000

Funding Competitive?: Yes

2025/1 - 2026/1
Principal Investigator

Compound testing with vascularized brain organoids model on AngioPlate platform

Funding Sources:
Merck & Co. Inc
Subcontract through OrganoBiotech, Inc.
Total Funding - 75,700
Funding Competitive?: No

2025/1 - 2026/1
Principal Investigator

Compound testing with engineered colon model to investigate immune responses in inflammation and fibrosis dynamics

Funding Sources:
Merck & Co. Inc
Subcontract through OrganoBiotech, Inc.
Total Funding - 357,900
Funding Competitive?: No

2023/12 - 2025/12
Co-investigator

ConTElab: Engineering Contractile Tissues for Tissue Regeneration and Wound Healing

Funding Sources:
Canada Foundation for Innovation (CFI)
John R. Evans Leaders Fund
Total Funding - 500,000
Funding Competitive?: Yes

Principal Investigator : Todd Hoare

2024/12 - 2025/12
Principal Investigator

Evaluation of Colon IBD model on AngioPlate

Funding Sources:
AbbVie
AbbVie Research contract
Total Funding - 270,000
Funding Competitive?: No

2024/4 - 2025/4
Co-investigator

Engineering perfusable vascular organoids for aging and chronic disease studies

Funding Sources:
McMaster University
Partnership Fund to Support University-Wide Initiatives
Total Funding - 8,381
Funding Competitive?: Yes

2024/4 - 2025/4
Principal Investigator

Self-driving Microphysiological Systems Lab

Funding Sources:
Natural Sciences and Engineering Research Council of Canada (NSERC)
Research Tools and Instruments Grant
Total Funding - 150,000
Funding Competitive?: Yes

Co-applicant : Todd Hoare

2023/4 - 2025/4
Co-investigator

Sustained liver engraftment with engineered functionally complete liver

Funding Sources:
STEM CELL Network
Stem Cell Network Project Grant
Total Funding - 175,000
Funding Competitive?: Yes

2024/1 - 2025/1

Macrophage Blood Vessel Co-culture Research Project

Principal Applicant

Funding Sources:
United Therapeutics Corporation
Research Contract
Total Funding - 271,400
Funding Competitive?: No

2019/10 - 2024/10
Principal Investigator

SynoPlate – Human physiology on demand

Funding Sources:
Canadian Institutes of Health Research (CIHR)
CIHR project grant
Total Funding - 684,675
Funding Competitive?: Yes

Co-applicant : Ana Konvalinka; Jeremy Hirota; Sandeep Raha

2018/7 - 2024/7
Principal Investigator

Smart scaffolds for guided tissue and organ assembly

Funding Sources:
Natural Sciences and Engineering Research Council of Canada (NSERC)
Discovery grant
Total Funding - 200,000
Funding Competitive?: Yes

2024/1 - 2024/6
Principal Applicant

Compound screening using AngioPlate blood vessel model

Funding Sources:
United Therapeutics Corporation
Research Contract
Total Funding - 29,000
Funding Competitive?: No

2019/12 - 2023/12
Principal Applicant

Laboratory of High-content Bioimaging for Organ-on-a-Chip systems

Funding Sources:
Canada Foundation for Innovation (CFI)
John R. Evans Leaders Fund
Total Funding - 300,000
Funding Competitive?: Yes

2018/7 - 2023/6
Principal Applicant

McMaster University Startup fund

Funding Sources:
McMaster University
Startup Fund
Total Funding - 162,000
Funding Competitive?: Yes

2019/4 - 2023/4
Principal Applicant

Pre-clinical evaluation of micro-tissue injection and self-assembly in vivo for cardiac repairs

Funding Sources:
Canadian Institutes of Health Research (CIHR)
CIHR Project grant
Total Funding - 386,324
Funding Competitive?: Yes

Co-applicant : Wenbin Liang

2021/11 - 2022/11
Principal Applicant

IFlowPlate – a universal platform for vascularizing organoids

Funding Sources:
Natural Sciences and Engineering Research Council of Canada (NSERC)

I2I Phase I Grant
Total Funding - 125,000
Funding Competitive?: Yes

2020/12 - 2021/12
Principal Applicant

Lightsheet microscopy for 3D bioimaging of engineered tissues and microphysiological systems

Funding Sources:
Natural Sciences and Engineering Research Council of Canada (NSERC)
RTI
Total Funding - 150,000
Funding Competitive?: Yes

2020/1 - 2021/1
Principal Applicant

IFlowPlate – A universal platform for vascularizing organoids

Funding Sources:
Natural Sciences and Engineering Research Council of Canada (NSERC)
NSERC I2I Market assessment grant
Total Funding - 20,000
Funding Competitive?: Yes

2019/6 - 2020/6
Co-applicant

3D printing of Organs

Funding Sources:
McMaster University
Big Idea Grant
Total Funding - 100,000
Funding Competitive?: Yes

Co-applicant : Ravi Selvaganapathy; Todd Hoare

Publications

Journal Articles

1. Clotet-Freixas, S.; Zaslaver, O.; Kotlyar, M.; Pastrello, C.; Quaile, A.T., McEvoy, C.M.; Saha, A.D.; Farkona, S.; Boshart, A.; Zorcic, K.; Neupane, S.; Manion, K.; Allen, M.; Chan, M.; Chen, X.; Arnold, A.P.; Sekula, P.; Steinbrenner, I.; Köttgen, A.; Dart, A.B.; Wicklow, B.; McGavock, J.M.; Blydt-Hansen, T.D.; Barrios, C.; Riera, M.; Soler, M.J.; Isenbrandt, A.; Lamontagne-Proulx, J.; Pradeloux, S.; Coulombe, K.; Soulet, D.; *Rajasekar, S.; Zhang, B.; John, R.; Mehrotra, A.; Gehring, A.; Puhka, M.; Jurisica, I.; Woo, M.; Scholey, J.W.; Röst, H.; Konvalinka, A. (2024). Sex differences in kidney metabolism may reflect sex-dependent outcomes in human diabetic kidney disease. SCIENCE TRANSLATIONAL MEDICINE. 16(737): eabm2090.
Published
Refereed?: Yes, Open Access?: No

2. Solsa Cariba, Avika Srivastava, Kendra Bronsema, Sonya Kouthouridis, Boyang Zhang, Samantha L. Payne. (2024). Innervated Coculture Device to Model Peripheral Nerve-Mediated Fibroblast Activation. ACS Biomaterials Science & Engineering. 10(20): 7566-7576.
Published
Refereed?: Yes, Open Access?: Yes

3. Rjaibi, S.; Jacques, E.; Ni, C.; Xu, B.; *Kouthouridis, S.; Sitolle, J.; Lad, H.; Gulati, N.; Li, N.T.; Ahn, H.; Ginsberg, H.; Zhang, B.; Le-Grand, F.; Gilbert, P.M.; McGuigan, A.P. (2024). A Cryopreservation Strategy for Myoblast Storage in Paper-Based Scaffolds for Inter-Laboratory Studies of Skeletal Muscle Health. Advanced Materials Interface. 24: 2400382.
Published
Refereed?: Yes, Open Access?: No

4. Zhao, Y; Landau, S; Okhovatian, S; Liu, C; Lu, R.X.Z.; Lai, B.F.L; Wu, Q.; Kieda, J.; Cheung, K.; Rajasekar, S.; Jozani, K.A.; Zhang, B.; and Radisic, M. (2024). Integrating organoids and organ-on-a-chip devices. Nature Reviews Bioengineering. 2: 588–608.
Published
Refereed?: Yes

5. Wu, Q.; Rafatian, N.; Wagner, K. T.; Blamer, J.; Smith, J.; Okhovatian, S.; Aggarwal, P.; Wang, E. Y.; Banerjee, A.; Zhao, Y.; Nash, T. R.; Lu, R. X. Z.; Portillo-Esquivel, L. E.; Li, C. Y.; Kuzmanov, U.; Mandla, S.; Virlee, E.; Landau, S.; Lai, B. F.; Gramolini, A. O.; Liu, C.; Fleischer, S.; Veres, T.; Vunjak-Novakovic, G.; Zhang, B.; Mossman, K.; Broeckel, U.; and Radisic, M. (2024). SARS-CoV-2 pathogenesis in an angiotensin II–induced heart-on-a-chip disease model and extracellular vesicle screening. Proceedings of the National Academy of Sciences. 121(28): e240358112.
Published
Refereed?: Yes, Open Access?: No

6. *Kouthouridis, S.; *Sotra, A.; *Khan, Z.; *Alvarado, J.; Raha, S.; Zhang, B. (2023). Modeling the Progression of Placental Transport from Early- to Late-Stage Pregnancy by Tuning Trophoblast Differentiation and Vascularization. Advanced Healthcare Materials. 12(32): 2301428.
Published
Refereed?: Yes

7. *Zhang, F.; *Lin, D.; *Rajasekar, S.; *Sotra, A.; Zhang, B. (2023). Pump-Less Platform Enables Long-Term Recirculating Perfusion of 3D Printed Tubular Tissues. Advanced Healthcare Materials. 12(27): 2300423.
Published
Refereed?: Yes, Open Access?: Yes

8. *Sotra, A.; *Jozania, K.A.; Zhang, B. (2023). A vascularized crypt-patterned colon model for high-throughput drug screening and disease modelling. Lab on a Chip. 23(15): 3370-3387.
Published
Refereed?: Yes, Open Access?: No

9. *Abdul, L.; *Xu, J.; *Sotra, A.; *Chaudary A.; *Gao J.; *Rajasekar S.; Zhang, B. (2022). D-CryptO: Deep learning-based analysis of colon organoid morphology from brightfield images. Lab on a Chip. 22: 4118-4128.
Published
Refereed?: Yes, Open Access?: No

10. *Kouthouridis, S.; *Robson, E.; *Hartung A.; Raha S.; Zhang B. (2022). Se(XY) Matters: The Importance of Incorporating Sex in Microphysiological. Trends in Biotechnology. 40: 1284-1298.
Published
Refereed?: Yes, Open Access?: No

11. *Rajasekar, S.; *Lin, D. S. Y.; *Zhang, F.; *Sotra, A.; Boshart, A.; Clotet-Freixas, S.; Liu, A.; Hirota, J. A.; Ogawa, S.; Konvalinka, A.; Zhang, B. (2022). Subtractive manufacturing with swelling induced stochastic folding of sacrificial materials for fabricating complex perfusable tissues in multi-well plates.Lab on a Chip. 22: 1929-1942.
Published
Refereed?: Yes, Open Access?: Yes

12. *Jozani, K.; *Kouthouridis, S.; Hirota J.; Zhang, B. (2022). Next generation preclinical models of lung development, physiology and disease. The Canadian Journal of Chemical Engineering. 101: 18-40.
Published
Refereed?: Yes, Open Access?: No

13. Wang, Y.; Singer, R.; Liu, X.; Inman, S. J.; Cao, Q.; Zhou, Q.; Noble, A.; Li, L.; Ask, K.; Kolb, M. R.; Ramsay, S.; Geng, F.; Zhang, B.; Shargail, Y.; Moran-Mirabal, J.; Dabaghi, M.; Hirota, J. A. (2022). The CaT Stretcher: An Open-Source System for Delivering Uniaxial Strain to Cells and Tissues (CaT). Frontiers in Bioengineering and Biotechnology. 22: 1934.
Published
Refereed?: Yes, Open Access?: No

14. Deering, J.; *Lin, D. S. Y.; D'Elia, A.; Zhang, B.; Grandfield, K. (2022). Fabrication of succinate-alginate xerogel films for in vitro coupling of osteogenesis and neovascularization. Biomaterials Advances. 141: 213122.
Published
Refereed?: Yes, Open Access?: No

15. *Lai, B. F. L.; Lu, R. X. Z.; Davenport Huyer, L.; Kakinoki, S.; Yazbeck, J.; Wang, E. Y.; Wu, Q.; Zhang, B.; Radisic, M. (2021). A well plate–based multiplexed platform for incorporation of organoids into an organ-on-a-chip system with a perfusable vasculature. Nature Protocols. 16(16): 2158–2189.
Published
Refereed?: Yes

16. *Sotra, A.; Zhang, B. (2021). Seeding A Growing Organ. Trends in Biotechnology. 39(8): 753-754.
Published
Refereed?: Yes

17. Dabaghi, M.; Saraei, N.; Carpio, M. B.; Nanduri, V.; Ungureanu, J.; Babi, M.; Chandiramohan, A.; Noble, A.; Revill, S. D.; Zhang, B.; Ask, K.; Kolb, M.; Shargall, Y.; Moran-Mirabal, J.; Hirota, J. A. (2021). A Robust Protocol for Decellularized Human Lung Bioink Generation Amenable to 2D and 3D Lung Cell Culture. Cells. 10(6): 2538.
Published
Refereed?: Yes

18. *Portillo, L.; and Zhang, B. (2020). Application of cell, tissue, and biomaterial delivery in cardiac regenerative therapy. ACS Biomaterial Science and Engineering. 7(3): 1000-1021.
Published
Refereed?: Yes

19. *Rajasekar, S.; *Lin, D.; *Abdul, L.; *Liu, A.; *Sotra, A.; *Zhang, F.; and *Zhang, B. (2020). IFlowPlate – A customized 384-well plate for the culture of perfusable vascularized colorectal organoids. Advanced Materials. 32(46): 2002974.
Published
Refereed?: Yes, Open Access?: No

20. *Abdul, L; *Rajasekar, S; *Lin, D.; *Raja, S.V.; *Sotra, A.; *Feng, Y.; *Liu, A.; Zhang, B. (2020). Deep-LUMEN Assay – Human epithelial spheroid localization and classification using deep learning. Lab on a Chip. 20(24): 4623-4631.
Published
Refereed?: Yes

21. *Hayward, K.L.; *Kouthouridis, S.; and Zhang, B. (2020). Organ-on-a-chip systems for modelling pathological tissue morphogenesis associated with fibrosis and cancer . ACS Biomaterial Science and Engineering. 7(7): 2900-2925.
Published
Refereed?: Yes

22. *Lin, D.; *Rajasekar, S.; *Marway, M.K.; and Zhang, B. (2020). From model system to therapy – Scalable production of perfusable vascularized liver spheroids in “open-top“ 384- well plate. ACS Biomaterial Science and Engineering. 7(7): 2964–2972.
Published
Refereed?: Yes

23. *Esquivel, L.E.P.; *Nanduri, V.; *Zhang, F.; Liang, W.; and Zhang, B. (2020). Z-wire – a micro-scaffold that supports guided tissue assembly and intramyocardium delivery for cardiac repair. Advanced Healthcare Materials. 9(14): 2000358.
Published
Refereed?: Yes

24. Zhao, Y.; Rafatian, N.; Feric, N. T.; Cox, B. J.; Aschar-Sobbi, R.; Wang, E. Y.; Aggarwal, P.; Zhang, B.; Conant, G.; Ronaldson-Bouchard, K.; Pahnke, A.; Protze, S.; Lee, J.H.; Davenport Huyer, L.; Jekic, D.; Wickeler, A.; Naguib,H.E.; Keller, K.; Vunjak-Novakovic, G.; Broeckel, U.; Backx, P.H.; and Radisic, M. (2019). A Platform for Generation of Chamber-Specific Cardiac Tissues and Disease Modeling. Cell. 176: 1-15.
Published
Refereed?: Yes

25. Parrish, J.; Lim, K.; Zhang, B.; Radisic, M.; Woodfield, T. B. F. (2019). New Frontiers for Biofabrication and Bioreactor Design in Microphysiological System Development. Trends in Biotechnology. 37(12): 1327-1343.
Published
Refereed?: Yes

26. Zhao, Y.; Wang, E. Y.; Davenport, L. H.; Liao, Y.; Yeager, K.; Vunjak-Novakovic, G.; Radisic, M.; Zhang, B. (2019). A multimaterial microphysiological platform enabled by rapid casting of elastic micro-wires. Advanced Healthcare Materials. 8(5): 1801187.
Published
Refereed?: Yes

27. Zhang, B; Radisic, M. (2019). Organ-level vascularization: The Mars Mission of Bioengineering. The Journal of Thoracic and Cardiovascular Surgery. 159(5): 2003-2007.
Published
Refereed?: Yes, Open Access?: Yes

28. Feric, N.; Aschar-Sobbi, R.; Zhao, Y.; *Zhang, B.; Ronaldson, K.; Pallotta, I.; Vunjak-Novakovic, G.; Radisic, M. (2018). Biowire™ II matured human engineered 3D cardiac tissue for drug discovery and cardiotoxicity applications. Journal of Pharmacological and Toxicological Methods. 93: 124.
Published
Refereed?: Yes, Open Access?: No

29. Korolj, A.; Laschinger, C.; James, C. H.; Hu, E.; Velikonja, C.; Smith, N.; Gu, I.; Ahadian, S.; Willette, R. N.; Radisic, M.; Zhang, B. (2018). Curvature facilitates podocyte culture in a biomimetic platform. Lab on a chip. 18: 3112-3128.
Published
Refereed?: Yes, Open Access?: No

30. Zhang, B.; *Lai, B. F. L.; Xie, R.; Huyer, L. D.; Montgomery, M.; Radisic, M. (2018). Microfabrication of AngioChip, a biodegradable polymer scaffold with micro fluidic vasculature. Nature Protocols. 13: 1793–1813.
Published
Refereed?: Yes, Open Access?: No

31. Zhang, B.; Korolj, A.; *Lai, B. F. L.; Radisic, M. (2018). Advances in organ-on-a-chip engineering. Nature Reviews Materials. 3: 257–278.
Published
Refereed?: Yes, Open Access?: No

32. *Lin, D. S. Y.; Guo, F.; Zhang, B. (2018). Modeling organ-specific vasculature with organ-on-a-chip devices. Nanotechnology. 30: 024002.
Published
Refereed?: Yes, Open Access?: No

Intellectual Property

Patents

1. Device and method for perfusion of 3D printed tissues. United States of America. 63/504,525. 2024/05/26.
   Patent Status: Pending
2. Compositions and methods for making and using three-dimensional tissue systems. United States of America. US20240230629A9. 2023/12/12.
   Patent Status: Pending
3. Cell culture system for perfusable networks of self assembled cells. United States of America. US20230174909A1. 2021/05/06.
   Patent Status: Pending
4. Tissue constructs with biocompatible linear scaffolds, methods of making and uses thereof. Canada. WO2020243832A1. 2020/06/03.
   Patent Status: Pending
5. A microphysiological platform with embedded electrodes for 3d tissue culture. United States of America. US20230075923A1. 2020/02/07.
   Patent Status: Pending

Presentations

1. (2024). Unlocking the potential of organoid and tissue models for drug discovery with engineered vasculatures. EMBO Building networks: Engineering in vascular biology, Spain
   Main Audience: Researcher
   Invited?: Yes, Keynote?: No
2. (2024). Simple Platform for Complex Biology. GSK Seminar, Canada
   Main Audience: Knowledge User
   Invited?: Yes, Keynote?: Yes
3. (2024). Modernizing drug discovery with automated and high-throughput Organ-on-a-Chip platform. Centre for Discovery of Cancer Research Seminar, Canada
   Main Audience: Researcher
   Invited?: Yes, Keynote?: Yes
4. (2024). Modernizing drug discovery: From organ-on-a-chip to AI-driven insights. Merck 3D Technologies Group Seminar, Canada
   Main Audience: Knowledge User
   Invited?: Yes, Keynote?: Yes
5. (2024). OrganoBiotech – Simple Platform for Complex Biology. McMaster Innovation Showcase, Canada
   Main Audience: General Public
   Invited?: Yes, Keynote?: Yes

Knowledge and Technology Translation

2021/1 - 2027/1 Co-founder, Involvement in/Creation of Start-up

Student/Postdoctoral Supervision

Doctorate [n=10]

2024/1 - 2028/1 Principal Supervisor	Neda Saraei, McMaster University, School of Biomedical Engineering Thesis/Project Title: Development of immunocompetent skin model on AngioPlate384 Present Position: PhD student
2023/9 - 2027/9 Principal Supervisor	Haniel Hashemi, McMaster University, Department of Chemical Engineering Thesis/Project Title: High-throughput blood vessel model for large-scale screening and studying vascular immune interaction Present Position: PhD student
2023/5 - 2028/5 Principal Supervisor	Brenda Truong, McMaster University, School of Biomedical Engineering Thesis/Project Title: Integrating light-sheet microscope with organ-on-a-chip system Present Position: PhD student
2023/5 - 2028/9 Principal Supervisor	Mathiew Child, McMaster University, Department of Chemical Engineering Thesis/Project Title: Development of colon organoid derived model with functional crypts and vasculature for modeling inflammatory bowel disease Present Position: PhD student
2023/5 - 2027/5 Principal Supervisor	Sara Deir, McMaster University, Department of Chemical Engineering Thesis/Project Title: Development of immunocompetent breathing alveoli model to recapitulate lung fibrosis Present Position: PhD student
2023/5 - 2025/5 Principal Supervisor	Madeleine Ludlow, McMaster University, School of Biomedical Engineering Thesis/Project Title: Development of placenta barrier model to study drug transport and pre-eclampsia in pregnancy Present Position: PhD Student
2022/9 - 2027/9 Principal Supervisor	Nicky Anvari, McMaster University, School of Biomedical Engineering Thesis/Project Title: Integrating Generative AI and large language model with high-throughput organ-on-a-chip systems for drug discovery Present Position: PhD Candidate
2021/9 - 2026/9 Principal Supervisor	Alexander Sotra, McMaster University, School of Biomedical Engineering Thesis/Project Title: Development of functional contractile airway and colon tubes for disease modeling Present Position: PhD Candidate and Vanier Scholar
2021/5 - 2026/5 Principal Supervisor	Kimia Jozani, McMaster University, School of Biomedical Engineering Thesis/Project Title: Development of high-throughput functional airway and alveolar models for disease modeling Present Position: PhD Candidate
2019/5 - 2024/5 Principal Supervisor	Feng Zhang, McMaster University, School of Biomedical Engineering Thesis/Project Title: ENGINEERING 3D PERFUSION PLATFORMS FOR RECAPITULATING IMMUNE RESPONSES IN VASCULARIZED MODELS Present Position: Research Associate